668 results on '"Laboratoire de Biologie Médicale"'
Search Results
2. COVID-19 Seroprevalence Study in French Guiana (EPI-COVID-POP)
- Author
-
Institut Pasteur de la Guyane, Laboratoire de biologie médicale, Institut Pasteur de la Guyane, Laboratoire de biologie médicale de Kourou, French Guiana, Laboratoire de biologie médicale du Centre hospitalier de Saint-Laurent du Maroni, French Guiana, Eurofins, and Centres Délocalisés de Prévention et de Soins, Centre Hospitalier Andrée Rosemon de Cayenne, Frech Guiana
- Published
- 2022
3. Biological Description of 109 Cases of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) from the French Network of BPDCN
- Author
-
Bernard Drenou, Sabrina Bouyer, Christophe Ferrand, Anne Galoisy, Francine Garnache Ottou, Christine Arnoulet, Blandine Bénet, Romaric Lacroix, Maïder Pagadoy, Fabrice Jardin, Marie-Christine Béné, Jean Feuillard, Philippe Saas, Chrystelle Vidal, Delphine Binda, Lydia Campos, Michel Ticchioni, Veronique Latger Cannard, Anne Roogy, Françoise Solly, Sylvie Daliphard, Elizabeth Macintyre, Maria Elena Noguera, Franck Geneviève, Françoise Schillinger, Carine Lecoq Lafon, Julien Guy, Valérie Bardet, Eric Deconinck, Anne Arnaud, Sabeha Biichle, Lucile Baseggio, Fanny Angelot Delettre, Liliana Vila, Zehaira Benseddik, Daniel Lusina, Magalie L. E. Garff Tavernier, Christophe Roumier, Véronique Salaun, Vahid Asnafi, Marie Christine Jacob, Eve Poret, Mikael Roussel, Estelle Seilles, Louis Benazet, Adriana Plesa, Veronique Harriverl, Franck Leroux, Jonchère, Laurent, Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) (RIGHT), Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté])-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Clinical Investigation Centre, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Franche-Comté (UFC), Centre d'Investigation Clinique 1432 (Dijon) - Module Plurithématique : Périnatalité Cancérologie Handicap et Ophtalmologie (CIC-P803), Institut National de la Santé et de la Recherche Médicale (INSERM)-Direction Générale de l'Organisation des Soins (DGOS)-Université de Bourgogne (UB), Laboratoire de Biologie Médicale, Centre hospitalier de Chartres (Chartres)-Hôpital Louis Pasteur [Chartres], Service d'Hématologie Cellulaire [Lille], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Contrôle de la Réponse Immune B et des Lymphoproliférations (CRIBL), Université de Limoges (UNILIM)-Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST FR CNRS 3503)-Centre National de la Recherche Scientifique (CNRS), Laboratoire d'Hématologie Cellulaire, Hospices Civils de Lyon (HCL), Laboratoire de Biologie Moléculaire de la Cellule (LBMC), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, Hematology Laboratory, Hospices Civils de Lyon, Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Biopathology, Haematology Department, Centre Hospitalier Emile Muller [Mulhouse] (CH E.Muller Mulhouse), Groupe Hospitalier de Territoire Haute Alsace (GHTHA)-Groupe Hospitalier de Territoire Haute Alsace (GHTHA), Centre hospitalier universitaire de Nantes (CHU Nantes), Département d'Immunologie, Centre Hospitalier Universitaire de Nice (CHU de Nice)-Groupe hospitalier l'Archet (Nice), Service d'hématologie biologique [Avicenne], Université Paris 13 (UP13)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Avicenne [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Laboratoire d'Hématologie Biologique, Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Descartes - Paris 5 (UPD5), Service hématologie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Imagine - Institut des maladies génétiques (IMAGINE - U1163), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Microenvironnement et cancer (MiCa), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Service d'Anatomie et Cytologie Pathologique B, Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-CHU Pontchaillou [Rennes], Groupe d'étude des proliférations lymphoïdes (GPL), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire de Biologie - Pathologie, CHU de Saint-Étienne Hôpital Nord (Saint Etienne), Hôpital Robert Debré, Hôpital Robert Debré-Centre Hospitalier Universitaire de Reims (CHU Reims), Laboratoire d'hématologie, Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM), Vascular research center of Marseille (VRCM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Aix Marseille Université (AMU), Laboratoire de biologie médicale, Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté]), Centre d'Investigation Clinique de Besançon (Inserm CIC 1431), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté]), Ingénierie et biologie cellulaire et tissulaire (IBCT (ex IFR133)), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté])-Université de Franche-Comté (UFC), Service d'Hématologie [CHRU Besançon], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Laboratoire d'Excellence : Lipoprotéines et Santé : prévention et Traitement des maladies Inflammatoires et du Cancer (LabEx LipSTIC), Institut National de la Recherche Agronomique (INRA)-Université Montpellier 2 - Sciences et Techniques (UM2)-Université Paris-Sud - Paris 11 (UP11)-École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut Gustave Roussy (IGR)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Université de Bourgogne (UB)-Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon)-Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL), UNICANCER-UNICANCER-Institut National de la Santé et de la Recherche Médicale (INSERM)-Fédération Francophone de la Cancérologie Digestive, FFCD-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté])-Centre National de la Recherche Scientifique (CNRS)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université de Montpellier (UM), Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) ( HOTE GREFFON ), Université de Franche-Comté ( UFC ) -Etablissement français du sang [Bourgogne-France-Comté] ( EFS [Bourgogne-France-Comté] ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université de Franche-Comté ( UFC ), Centre d'Investigation Clinique 1432 (Dijon) - Module Plurithématique : Périnatalité Cancérologie Handicap et Ophtalmologie ( CIC-P803 ), Université de Bourgogne ( UB ) -Direction Générale de l'Organisation des Soins (DGOS)-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Centre Hospitalier Régional Universitaire [Lille] ( CHRU Lille ), Contrôle de la Réponse Immune B et des Lymphoproliférations ( CRIBL ), Université de Limoges ( UNILIM ) -Génomique, Environnement, Immunité, Santé, Thérapeutique ( GEIST FR CNRS 3503 ) -Centre National de la Recherche Scientifique ( CNRS ), Hospices Civils de Lyon ( HCL ), Laboratoire de Biologie Moléculaire de la Cellule ( LBMC ), École normale supérieure - Lyon ( ENS Lyon ) -Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Centre de Recherche en Cancérologie de Lyon ( CRCL ), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 ( UCBL ), Centre Hospitalier Emile Muller [Mulhouse] ( CH E.Muller Mulhouse ), Groupe Hospitalier de Territoire Haute Alsace ( GHTHA ) -Groupe Hospitalier de Territoire Haute Alsace ( GHTHA ), Centre hospitalier universitaire de Nantes ( CHU Nantes ), Centre Hospitalier Universitaire de Nice ( CHU de Nice ) -Groupe hospitalier l'Archet (Nice), Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Avicenne-Université Paris 13 ( UP13 ), CHU Cochin [AP-HP]-Université Paris Descartes - Paris 5 ( UPD5 ), Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Imagine - Institut des maladies génétiques ( IMAGINE - U1163 ), Centre National de la Recherche Scientifique ( CNRS ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université Paris Descartes - Paris 5 ( UPD5 ), Microenvironnement et cancer ( MiCa ), Université de Rennes 1 ( UR1 ), Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -CHU Pontchaillou [Rennes], Groupe d'étude des proliférations lymphoïdes ( GPL ), Université de Rouen Normandie ( UNIROUEN ), Normandie Université ( NU ) -Normandie Université ( NU ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Hôpital Robert Debré-Centre Hospitalier Universitaire de Reims ( CHU Reims ), CHU Angers, Vascular research center of Marseille ( VRCM ), Aix Marseille Université ( AMU ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Etablissement français du sang [Bourgogne-France-Comté] ( EFS [Bourgogne-France-Comté] ), Centre d'Investigation Clinique de Besançon ( CICB ), Etablissement Français du Sang Bourgogne Franche-Comté-Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université de Franche-Comté ( UFC ), Ingénierie et biologie cellulaire et tissulaire ( IBCT (ex IFR133) ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Etablissement français du sang [Bourgogne-France-Comté] ( EFS [Bourgogne-France-Comté] ) -Université de Franche-Comté ( UFC ), Laboratoire d'Hématologie, Hôpital Jean Minjoz-Université de Franche-Comté ( UFC ), Laboratoire d'Excellence : Lipoprotéines et Santé : prévention et Traitement des maladies Inflammatoires et du Cancer ( LabEx LipSTIC ), Institut National de la Recherche Agronomique ( INRA ) -Université Montpellier 2 - Sciences et Techniques ( UM2 ) -Université Paris-Sud - Paris 11 ( UP11 ) -École pratique des hautes études ( EPHE ) -Institut Gustave Roussy ( IGR ) -Centre Hospitalier Régional Universitaire de Nancy ( CHRU Nancy ) -Université de Bourgogne ( UB ) -Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand ( CHU Dijon ) -Centre Régional de Lutte contre le cancer - Centre Georges-François Leclerc ( CRLCC - CGFL ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Fédération Francophone de la Cancérologie Digestive, FFCD-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Etablissement français du sang [Bourgogne-France-Comté] ( EFS [Bourgogne-France-Comté] ) -Centre National de la Recherche Scientifique ( CNRS ) -Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université de Franche-Comté ( UFC ), Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) (HOTE GREFFON), Université de Franche-Comté (UFC)-Etablissement français du sang [Bourgogne-France-Comté] (EFS [Bourgogne-France-Comté])-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Bourgogne (UB)-Direction Générale de l'Organisation des Soins (DGOS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de la Recherche Scientifique (CNRS)-Université de Limoges (UNILIM)-Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST FR CNRS 3503), École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Centre de Recherche en Cancérologie de Lyon (CRCL), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université Paris 13 (UP13)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Avicenne, CHU Cochin [AP-HP]-Université Paris Descartes - Paris 5 (UPD5), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Necker - Enfants Malades [AP-HP], Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Etablissement français du sang [Bourgogne-France-Comté] (EFS [Bourgogne-France-Comté]), Centre d'Investigation Clinique de Besançon (CICB), Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement Français du Sang Bourgogne Franche-Comté-Université de Franche-Comté (UFC), Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon)-Etablissement français du sang [Bourgogne-France-Comté] (EFS [Bourgogne-France-Comté])-Université de Franche-Comté (UFC), Hôpital Jean Minjoz-Université de Franche-Comté (UFC), Institut National de la Recherche Agronomique (INRA)-Université Montpellier 2 - Sciences et Techniques (UM2)-Université Paris-Sud - Paris 11 (UP11)-École pratique des hautes études (EPHE)-Institut Gustave Roussy (IGR)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Université de Bourgogne (UB)-Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon)-Centre Régional de Lutte contre le cancer - Centre Georges-François Leclerc (CRLCC - CGFL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Fédération Francophone de la Cancérologie Digestive, FFCD-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Etablissement français du sang [Bourgogne-France-Comté] (EFS [Bourgogne-France-Comté])-Centre National de la Recherche Scientifique (CNRS)-Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon)-Université de Franche-Comté (UFC)-Université de Montpellier (UM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS BFC)-Université de Franche-Comté (UFC), École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Centre Hospitalier Universitaire de Nice (CHU Nice)-Groupe hospitalier l'Archet (Nice), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Université de Rennes (UR)-CHU Pontchaillou [Rennes], Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E), Etablissement français du sang [Bourgogne-Franche-Comté] (EFS BFC), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS BFC)-Université de Franche-Comté (UFC), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS BFC)-Université de Franche-Comté (UFC), Institut National de la Recherche Agronomique (INRA)-Université Montpellier 2 - Sciences et Techniques (UM2)-Université Paris-Sud - Paris 11 (UP11)-École Pratique des Hautes Études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut Gustave Roussy (IGR)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Bourgogne (UB)-Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon)-Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL), UNICANCER-UNICANCER-Institut National de la Santé et de la Recherche Médicale (INSERM)-Fédération Francophone de la Cancérologie Digestive, FFCD-Université de Montpellier (UM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS BFC)-Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté])-Université de Franche-Comté (UFC), and UNICANCER-UNICANCER-Institut National de la Santé et de la Recherche Médicale (INSERM)-Fédération Francophone de la Cancérologie Digestive, FFCD-Université de Montpellier (UM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté])-Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC)
- Subjects
0303 health sciences ,Pathology ,medicine.medical_specialty ,[ SDV ] Life Sciences [q-bio] ,[SDV]Life Sciences [q-bio] ,Immunology ,Cell Biology ,Hematology ,Blastic plasmacytoid dendritic cell neoplasm ,Biology ,Biochemistry ,3. Good health ,[SDV] Life Sciences [q-bio] ,03 medical and health sciences ,0302 clinical medicine ,Myeloid cells ,medicine ,Skin lesion ,030304 developmental biology ,030215 immunology - Abstract
Blastic plasmacytoid dendritic cell neoplasm is a clonal disease derived from precursors of plasmacytoid dendritic cells (pDC). It is a rare neoplasm involving the skin which may or may not be associated from the outset with a leukemic component. The disease invariably progresses to aggressive leukemic dissemination, leading to a differential diagnosis with acute leukemia. In 2004, we set up a French network to recruit biological data at diagnosis. Diagnosis was according to recommendations (Swerdlow et al, 2008), with, in addition, a mandatory panel of pDC markers (Garnache-Ottou et al, 2009) detected by flow cytometry or by immunohistochemistry on infiltrated blood, bone marrow or cutaneous lesions. In total, 109 cases of BPDCN were included in 35 hospitals (2000-2013). BPDCN is more prevalent in men (sex ratio 4.4/1) and in elderly subjects (median age: 63 years; 7 patients were Immunophenotype showed that HLA-DR and CD4 were expressed in all cases, but 4 cases did not express CD56 (confirmed using 3 different antibodies). Expression of markers of others hematopoietic lineages was frequent. Among myeloid markers, the most frequent was CD33 (46%), followed by CD117 (23%), whereas CD13, CD11c, CD15 and CD65 were rarely expressed. Monocyte markers (CD14, CD64, CD11b) and myeloperoxidase were never expressed. For the T lineage, CD2 and CD7 were the most frequent (62% and 58% respectively) whereas CD5 was rare (7%). No cytoplasmic or surface CD3 were detected. For the B lineage, CD22 was expressed in 16%, and low levels of cCD79a in 5%. Both were never expressed together, and no CD19, CD20 and immunoglobulins were found. Generally, we observed one of these antigens (Ags) per case, but in 44% of cases, there was a combination of 2 or 3 Ags from 2 or 3 different lineages. Immature Ags such as CD34 and CD133 were never found, and Tdt was found in 14% of cases. Cytogenetic analysis revealed abnormal caryotype in 65% of the 78 caryotypes evaluated, with 20 cases having a complex caryotype. The frequency of the chromosomal abnormalities involved are shown in Figure 1H. In conclusion, we describe the largest series of BPDCN to date in the literature. Detailed clinical and biological data at presentation allow improved recognition of this rare form of acute and aggressive leukemia, enabling early initiation of appropriate management. Figure 1. A: Blood cell count in 109 BPDCN patients at diagnosis. Bars represent the median. B: Typical BPDCN morphology. C: In this case, the nuclei were peripheral, cytoplasm presented heterogenous basophilia, vacuoles were rare but large pseudopodia are frequent. D: Typical morphology with frequent microvacuoles under the cytoplasmic membrane. E: Immature morphology. F: Pseudolymphocytic morphology. G: Presence of dysplasia in myeloid cells with Auer Rods in the granulocytes. The morphology of the Blastic cells is typical. H. Chromosomal abnormalities in 78 caryotypes evaluated: The histogram represents the number of cases in which each chromosome was involved (deletion, gain, translocations). Figure 1. A: Blood cell count in 109 BPDCN patients at diagnosis. Bars represent the median. B: Typical BPDCN morphology. C: In this case, the nuclei were peripheral, cytoplasm presented heterogenous basophilia, vacuoles were rare but large pseudopodia are frequent. D: Typical morphology with frequent microvacuoles under the cytoplasmic membrane. E: Immature morphology. F: Pseudolymphocytic morphology. G: Presence of dysplasia in myeloid cells with Auer Rods in the granulocytes. The morphology of the Blastic cells is typical. H. Chromosomal abnormalities in 78 caryotypes evaluated: The histogram represents the number of cases in which each chromosome was involved (deletion, gain, translocations). Disclosures Bardet: Celgene: Research Funding. Deconinck:CHUGAI: Other: Travel for international congress; PFIZER: Research Funding; ROCHE: Research Funding; NOVARTIS: Other: Travel for international congress; ALEXION: Other: Travel for international congress; JANSSEN: Other: Travel for international congress; LFB loboratory: Consultancy.
- Published
- 2015
4. Hepatitis B in Senegal: A Successful Infant Vaccination Program but Urgent Need to Scale Up Screening and Treatment (ANRS 12356 AmBASS survey)
- Author
-
Périères, Lauren, Diallo, Aldiouma, Marcellin, Fabienne, Nishimwe, Marie Libérée, Ba, El Hadji, Coste, Marion, Lo, Gora, Halfon, Philippe, Touré Kane, Coumba, Maradan, Gwenaëlle, Carrieri, Patrizia, Diouf, Assane, Shimakawa, Yusuke, Sokhna, Cheikh, Boyer, Sylvie, Bérenger, Cyril, Bousmah, Marwan al Qays, de Seze, Maëlle, Djaogol, Tchadine, Treibich, Carole, Ba, Elhadji, Dièye, Fambaye, Faye, Elhadji Bilal, Ndiaye, Assane, Sow, Mouhamadou Baba, Ndiaye, Anna Julienne Selbé, Ndiour, Samba, Mohamed, Sofiane, Rouveau, Nicolas, Cortès, Maria‐Camila Calvo, Laborde‐Balen, Gabrièle, Audibert, Martine, Fall, Fatou, Gueye, Ibrahima, Lacombe, Karine, Seydi, Moussa, Tuaillon, Edouard, Vray, Muriel, Vecteurs - Infections tropicales et méditerranéennes (VITROME), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées [Brétigny-sur-Orge] (IRBA), Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD), Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut des sciences de la santé publique [Marseille] (ISSPAM), Aix-Marseille Sciences Economiques (AMSE), École des hautes études en sciences sociales (EHESS)-Aix Marseille Université (AMU)-École Centrale de Marseille (ECM)-Centre National de la Recherche Scientifique (CNRS), Institut de Recherche en Santé, de Surveillance Épidémiologique et de Formation [Dakar, Sénégal] (IRESSEF), ALPHABIO - Laboratoire de biologie médicale, Hôpital Européen [Fondation Ambroise Paré - Marseille], Observatoire régional de la santé Provence-Alpes-Côte d'Azur [Marseille] (ORS PACA), Epidémiologie des Maladies Emergentes - Emerging Diseases Epidemiology, Université Paris Cité (UPCité)-Pasteur-Cnam Risques infectieux et émergents (PACRI), Institut Pasteur [Paris] (IP)-Conservatoire National des Arts et Métiers [CNAM] (CNAM), HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-Université Paris Cité (UPCité)-Institut Pasteur [Paris] (IP)-Conservatoire National des Arts et Métiers [CNAM] (CNAM), HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM), ANRS 12356 AmBASS Survey Study Group: Cyril Bérenger, Marwan Al Qays Bousmah, Sylvie Boyer, Patrizia Carrieri, Marion Coste, Maëlle de Seze, Tchadine Djaogol, Gwenaëlle Maradan, Fabienne Marcellin, Carole Treibich, Elhadji Ba, Aldiouma Diallo, Fambaye Dièye, Assane Diouf, Elhadji Bilal Faye, Assane Ndiaye, Lauren Périères, Cheikh Sokhna, Mouhamadou Baba Sow, Coumba Touré Kane, Gora Lo, Anna Julienne Selbé Ndiaye, Samba Ndiour, Philippe Halfon, Sofiane Mohamed, Nicolas Rouveau, Maria-Camila Calvo Cortès, Gabrièle Laborde-Balen, Martine Audibert, Fatou Fall, Ibrahima Gueye, Karine Lacombe, Moussa Seydi, Yusuke Shimakawa, Edouard Tuaillon, Muriel Vray, Lhuillier, Elisabeth, and Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées (IRBA)
- Subjects
Adult ,Hepatitis B Surface Antigens ,Adolescent ,Hepatology ,Vaccination ,Infant ,Hepatitis B ,[SHS.ECO]Humanities and Social Sciences/Economics and Finance ,Senegal ,3. Good health ,Young Adult ,03 medical and health sciences ,Cross-Sectional Studies ,0302 clinical medicine ,Humans ,Female ,Hepatitis B Vaccines ,030211 gastroenterology & hepatology ,030212 general & internal medicine ,[SHS.ECO] Humanities and Social Sciences/Economics and Finance ,Child - Abstract
International audience; Senegal introduced the infant hepatitis B virus (HBV) vaccination in 2004 and recently committed to eliminating hepatitis B by 2030. Updated epidemiological data are needed to provide information on the progress being made and to develop new interventions. We estimated the prevalence of hepatitis B surface antigen (HBsAg) in children and adults living in rural Senegal and assessed hepatitis B treatment eligibility. A cross-sectional population-based serosurvey of HBsAg was conducted in 2018-2019 in a large sample (n = 3,118) of residents living in the Niakhar area (Fatick region, Senegal). Individuals positive for HBsAg subsequently underwent clinical and biological assessments. Data were weighted for age and sex and calibrated to be representative of the area's population. Among the 3,118 participants, 206 were HBsAg positive (prevalence, 6.9%; 95% confidence interval [CI], 5.6-8.1). Prevalence varied markedly according to age group in individuals aged 0-4, 5-14, 15-34, and >= 35 years as follows: 0.0% (95% CI, 0.00-0.01); 1.5% (95% CI, 0.0-2.3); 12.4% (95% CI, 9.1-15.6); and 8.8% (95% CI, 6.1-11.5), respectively. Of those subsequently assessed, 50.9% (95% CI, 41.8-60.0) had active HBV infection; 4 (2.9%; 95% CI, 0.9-9.4) were eligible for hepatitis B treatment. Conclusion: In this first population-based serosurvey targeting children and adults in rural Senegal, HBsAg prevalence was very low in the former, meeting the World Health Organization's (WHO) < 1% HBsAg 2020 target; however, it was high in young adults (15-34 years old) born before the HBV vaccine was introduced in 2004. To reach national and WHO hepatitis elimination goals, general population testing (particularly for adolescents and young adults), care, and treatment scale-up need to be implemented.
- Published
- 2021
- Full Text
- View/download PDF
5. Targeted Proteomics Analysis of Staphylococcal Superantigenic Toxins in Menstrual Fluid from Women with Menstrual Toxic Shock Syndrome (mTSS)
- Author
-
Marie Courçon, Cédric Badiou, Mathilde Louwagie, Sibyle Etievant, Michel Jaquinod, Gérard Lina, Virginie Brun, BioSanté (UMR BioSanté), Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Recherche Interdisciplinaire de Grenoble (IRIG), Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Grenoble Alpes (UGA), Centre International de Recherche en Infectiologie (CIRI), École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Laboratoire de Biologie Médicale MultiSites [Bron] (LBMMS), Hospices Civils de Lyon (HCL)-Centre de Biologie et Pathologie Est [Bron] (CBPE), Hôpital de la Croix-Rousse [CHU - HCL], Hospices Civils de Lyon (HCL), Clinatec - Centre de recherche biomédicale Edmond J.Safra (SCLIN), Commissariat à l'énergie atomique et aux énergies alternatives - Laboratoire d'Electronique et de Technologie de l'Information (CEA-LETI), Direction de Recherche Technologique (CEA) (DRT (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Direction de Recherche Technologique (CEA) (DRT (CEA)), and Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre Hospitalier Universitaire [Grenoble] (CHU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Grenoble Alpes (UGA)
- Subjects
proteomics ,mass spectrometry ,staphylococcal toxic shock syndrome ,menstrual fluid ,TSST-1 ,Health, Toxicology and Mutagenesis ,[SDV]Life Sciences [q-bio] ,Toxicology - Abstract
International audience; Menstrual toxic shock syndrome (mTSS) is a rare life-threatening febrile illness that occurs in women using intravaginal menstrual protection. It is caused by toxic shock syndrome toxin 1 (TSST-1) produced by Staphylococcus aureus, triggering a sudden onset of rash and hypotension, subsequently leading to multiple organ failure. Detecting TSST-1 and S. aureus virulence factors in menstrual fluid could accelerate the diagnosis and improve therapeutic management of mTSS. However, menstrual fluid is a highly complex matrix, making detection of bacterial toxins challenging. Here, we present a mass-spectrometry-based proteomics workflow for the targeted, quantitative analysis of four S. aureus superantigenic toxins in menstrual fluids (TSST-1, SEA, SEC, and SED). This method was applied to characterize toxin levels in menstrual fluids collected from patients with mTSS and healthy women. Toxins were detectable in samples from patients with mTSS and one healthy donor at concentrations ranging from 0 to 0.46 µg/mL for TSST-1, and 0 to 1.07 µg/mL for SEC. SEA and SED were never detected in clinical specimens, even though many S. aureus strains were positive for the corresponding genes. The method presented here could be used to explore toxin production in vivo in users of intravaginal devices to improve the diagnosis, understanding, and prevention of mTSS.
- Published
- 2022
- Full Text
- View/download PDF
6. Clinical relevance of cagA and vacA gene polymorphisms in Helicobacter pylori isolates from Senegalese patients
- Author
-
Sébastien Breurec, Benoit Garin, Josette Raymond, Cheikh Fall, Michel Huerre, Abdoulaye Seck, D. Dia, M. Mbengue, R. Michel, D. Côme, F.B. Dieye, Jean-Michel Thiberge, Dionyssios N. Sgouras, Sylvain Brisse, Laboratoire de Biologie médicale, Institut Pasteur de Bangui, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP), Laboratoire de Biologie Médicale [Dakar, Sénégal], Institut Pasteur de Dakar, Conditions Extrêmes et Matériaux : Haute Température et Irradiation (CEMHTI), Université d'Orléans (UO)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), Pathogénie Microbienne Moléculaire, Institut Pasteur [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM), Os et articulations, Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Réseau International des Instituts Pasteur (RIIP), Unité de Bactériologie Expérimentale [Antananarivo, Madagascar] (IPM), Institut Pasteur de Madagascar, Défense innée et inflammation, Service d'hépato-gastroentérologie, CHU Aristide Le Dantec, Bactériologie médicale et Environnementale, Institut Pasteur Hellénique, Génotypage des Pathogènes et Santé Publique (Plate-forme) (PF8), Institut Pasteur [Paris], Département de Gastro-entérologie, Centre Hospitaler Le Dantec, Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Institut Pasteur [Paris] (IP)
- Subjects
Male ,EPIYA ,Gastroenterology ,Polymerase Chain Reaction ,0302 clinical medicine ,Aged, 80 and over ,0303 health sciences ,cagA ,biology ,Coinfection ,Incidence (epidemiology) ,mixed infections ,Incidence ,General Medicine ,Middle Aged ,Senegal ,3. Good health ,Infectious Diseases ,Gastritis ,Population study ,030211 gastroenterology & hepatology ,Female ,medicine.symptom ,vacA ,Microbiology (medical) ,Adult ,DNA, Bacterial ,medicine.medical_specialty ,Peptic Ulcer ,Adolescent ,Genotype ,Molecular Sequence Data ,Helicobacter Infections ,03 medical and health sciences ,Young Adult ,Bacterial Proteins ,Stomach Neoplasms ,Internal medicine ,medicine ,CagA ,Humans ,Allele ,030304 developmental biology ,Aged ,Antigens, Bacterial ,Polymorphism, Genetic ,Molecular epidemiology ,Helicobacter pylori ,Cancer ,Sequence Analysis, DNA ,biology.organism_classification ,medicine.disease ,bacterial infections and mycoses ,[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology ,digestive system diseases ,Immunology ,Africa ,bacteria ,H. pylori - Abstract
The molecular epidemiology of Helicobacter pylori in Africa is poorly documented. From January 2007 to December 2008, we investigated 187 patients with gastric symptoms in one of the main tertiary hospitals in Dakar, Senegal. One hundred and seventeen patients were culture-positive for H. pylori. Polymorphisms in vacA and cagA status were investigated by PCR; the 3′-region of cagA was sequenced, and EPIYA motifs were identified. Bacterial heterogeneity within individuals was extensively assessed by using an approach based on vacA and cagA heterogeneity. Fourteen per cent of H. pylori -positive patients displayed evidence of mixed infection, which may affect disease outcome. Patients with multiple vacA alleles were excluded from subsequent analyses. Among the final study population of 105 patients, 29 had gastritis only, 61 had ulcerated lesions, and 15 had suspicion of neoplasia based on endoscopic findings. All cases of suspected neoplasia were histologically confirmed as gastric cancer (GC). The cagA gene was present in 73.3% of isolates. CagA proteins contained zero (3.7%), one (93.9%) or two (2.4%) EPIYA-C segments, and all were western CagA. Most of the isolates possessed presumed high-vacuolization isotypes (s1i1m1 (57.1%) or s1i1m2 (21.9%)). Despite the small number of cases, GC was associated with cagA (p 0.03), two EPIYA-C segments in the C-terminal region of CagA (p 0.03), and the s1 vacA allele (p 0.002). Multiple EPIYA-C segments were less frequent than reported in other countries, possibly contributing to the low incidence of GC in Senegal.
- Published
- 2011
- Full Text
- View/download PDF
7. Développement et application de méthodes pour l'analyse de la composition du microbiote humain dans un contexte clinique en utilisant des stratégies de séquençage alternatives
- Author
-
Goutorbe, Benoît, Mathématiques et Informatique Appliquées du Génome à l'Environnement [Jouy-En-Josas] (MaIAGE), Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), ALPHABIO - Laboratoire de biologie médicale, Université Paris-Saclay, Sophie Schbath, Ghislain Bidaut, Philippe Halfon, and STAR, ABES
- Subjects
Microbiote ,Santé ,[SDV.BIBS] Life Sciences [q-bio]/Quantitative Methods [q-bio.QM] ,[SDV.MHEP] Life Sciences [q-bio]/Human health and pathology ,Bioinformatique ,Bioinformatics ,Health ,Microbiota ,NGS ,Metagenomics ,[SDV.BIBS]Life Sciences [q-bio]/Quantitative Methods [q-bio.QM] ,[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology ,Métagénomique - Abstract
The microbiota and its relation to human health are nowadays widely studied. High-throughput sequencing has greatly contributed to the rapid development of this field by allowing the identification and quantification of all microorganisms in a given sample, without the prior constraints of isolation and culture. Two sequencing strategies are mainly used: metabarcoding, which consists of sequencing only one marker gene, which is cost-efficient but not very precise; and shotgun metagenomics, which consists of sequencing all the DNA present in a sample, allowing a better taxonomic resolution and a functional characterization but whose cost is sometimes prohibitive. This thesis focuses on two intermediate alternative sequencing strategies that are more precise than metabarcoding but less expensive than shotgun metagenomics. We first evaluated the relevance of shallow shotgun metagenomics for studying the gut microbiota. We developed a reliable and optimized analysis pipeline, and then demonstrated the ability of this approach to reconstruct taxonomic profiles and differences between patients. In a second step, we developed an integrative multi-marker metabarcoding approach to characterize the vaginal microbiota, which takes advantage of the universality and discriminatory capacity of each marker. This thesis work also includes the analysis of data from two clinical projects, one on the standardization of the pre-analytical protocol and the other on the links between the gut microbiota and an autoimmune disease, systemic erythematosus lupus., Le microbiote et ses liens avec la santé humaine sont aujourd'hui très étudiés. Le séquençage à haut débit a grandement contribué à l'essor fulgurant du domaine en permettant d'identifier et de quantifier finement tous les micro-organismes d'un échantillon donné, sans les contraintes préalables d'isolement et de culture. Deux stratégies de séquençage sont majoritairement utilisées : le métabarcoding, qui consiste à ne séquencer qu'un gène marqueur ce qui est peu coûteux mais peu résolutif ; et la métagénomique shotgun, qui consiste à séquencer tout l'ADN présent dans un échantillon, permettant une meilleure résolution taxonomique et une caractérisation fonctionnelle mais dont les coûts sont parfois prohibitifs. Cette thèse s'intéresse à deux stratégies de séquençage intermédiaires, plus résolutives que le métabarcoding tout en étant moins coûteuses que la métagénomique shotgun. Nous avons dans un premier temps évalué la pertinence de la métagénomique shotgun à faible profondeur de séquençage pour l'étude du microbiote intestinal. Pour cela, nous avons développé un pipeline d'analyse fiable et optimisé, puis montré la capacité de notre méthode à reconstruire les profils taxonomiques et discriminer les patients. Dans un deuxième temps, nous avons développé une approche intégrative de métabarcoding multi-marqueurs pour caractériser le microbiote vaginal, qui permet de tirer parti de l'universalité et du pouvoir discriminant de chaque marqueur. Ce travail de thèse inclut également l'analyse de données issus de deux projets cliniques distincts, l'un portant sur la standardisation du protocole pré-analytique et l'autre sur les liens entre le microbiote intestinal et une maladie auto-immune, le lupus érythémateux systémique.
- Published
- 2022
8. Gut microbiota in systemic lupus erythematosus patients and lupus mouse model: a cross species comparative analysis for biomarker discovery
- Author
-
Eya Toumi, Benoit Goutorbe, Anne Plauzolles, Marion Bonnet, Soraya Mezouar, Muriel Militello, Jean-Louis Mege, Laurent Chiche, Philippe Halfon, Microbes évolution phylogénie et infections (MEPHI), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), ALPHABIO - Laboratoire de biologie médicale, Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Mathématiques et Informatique Appliquées du Génome à l'Environnement [Jouy-En-Josas] (MaIAGE), Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Institut Hospitalier Universitaire Méditerranée Infection (IHU Marseille), Hôpital de la Conception [CHU - APHM] (LA CONCEPTION), Pôle Médecine Interne, Maladies Infectieuses, Hématologie [Hôpital Européen, Marseille], and Hôpital Européen de Marseille (HEM)
- Subjects
Adult ,gut microbiota ,Bacteroidetes ,[SDV]Life Sciences [q-bio] ,Immunology ,Firmicutes ,biomarkers ,Biodiversity ,dysbiosis ,health care ,Gastrointestinal Microbiome ,Mice ,systemic lupus erythematosus ,Animals ,Humans ,Lupus Erythematosus, Systemic ,Immunology and Allergy ,disease activity ,outcome assessment - Abstract
An increasing number of studies have provided strong evidence that gut microbiota interact with the immune system and stimulate various mechanisms involved in the pathogenesis of auto-immune diseases such as Systemic Lupus Erythematosus (SLE). Indeed, gut microbiota could be a source of diagnostic and prognostic biomarkers but also hold the promise to discover novel therapeutic strategies. Thus far, specific SLE microbial signatures have not yet been clearly identified with alteration patterns that may vary between human and animal studies. In this study, a comparative analysis of a clinically well-characterized cohort of adult patients with SLE showed reduced biodiversity, a lower Firmicutes/Bacteroidetes (F/B) ratio, and six differentially abundant taxa compared with healthy controls. An unsupervised clustering of patients with SLE patients identified a subgroup of patients with a stronger alteration of their gut microbiota. Interestingly, this clustering was strongly correlated with the disease activity assessed with the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score (p = 0.03, odd ratio = 15) and the identification of specific alterations involving the F/B ratio and some different taxa. Then, the gut microbiota of pristane-induced lupus and control mice were analyzed for comparison with our human data. Among the six differentially abundant taxa of the human disease signature, five were common with our murine model. Finally, an exhaustive cross-species comparison between our data and previous human and murine SLE studies revealed a core-set of gut microbiome species that might constitute biomarker panels relevant for future validation studies.
- Published
- 2022
- Full Text
- View/download PDF
9. Human Q Fever on the Guiana Shield and Brazil: Recent Findings and Remaining Questions
- Author
-
Gaëlle Walter, E. Beillard, Pauline Thill, Elba Regina Sampaio de Lemos, Vincent Pommier de Santi, María Mercedes Panizo, Loïc Epelboin, Magalie Demar, Alessia Melzani, S. Vreden, Philippe Abboud, Paule Letertre-Gibert, M. Boutrou, Carole Eldin, Julman Rosiris Cermeño, Félix Djossou, Jorlan Fernandes, Lucas Perez, Jacobus H. de Waard, Unité des Maladies Infectieuses et Tropicales (UMIT), Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française], Centre d'Investigation Clinique Antilles-Guyane (CIC - Antilles Guyane), Université des Antilles et de la Guyane (UAG)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pointe-à-Pitre/Abymes [Guadeloupe] -CHU de Fort de France-Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française], Ecosystemes Amazoniens et Pathologie Tropicale (EPat), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Guyane (UG), Vecteurs - Infections tropicales et méditerranéennes (VITROME), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées (IRBA), Service Universitaire des Maladies Infectieuses et du Voyageur [Tourcoing], Centre Hospitalier Tourcoing, Centre d'épidémiologie et de santé publique des armées [Marseille] (CESPA), Service de Santé des Armées, Laboratoire Hospitalo-Universitaire de Parasitologie-Mycologie, Coordination Régionale de la lutte contre le Virus de L'Immunodéficience Humaine (COREVIH)-Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française]-Université des Antilles (UA), Instituto Oswaldo Cruz / Oswaldo Cruz Institute [Rio de Janeiro] (IOC), Fundação Oswaldo Cruz (FIOCRUZ), Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP), Universidad Central de Venezuela (UCV), Instituto Nacional de Higiene 'Rafael Rangel' - National Institute of Hygiene Rafael Rangel [Caracas, Venezuela], Academic Hospital Paramaribo [Paramaribo, Suriname], Laboratoire de biologie médicale [Cayenne, Guyane française] (LBM), Institut Pasteur de la Guyane, Universidad de Oriente, COMBE, Isabelle, Institut de Recherche Biomédicale des Armées (IRBA)-Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées [Brétigny-sur-Orge] (IRBA), and Fundação Oswaldo Cruz / Oswaldo Cruz Foundation (FIOCRUZ)
- Subjects
Bacterial zoonosis ,Latin Americans ,Community-acquired pneumonia ,Amazonian ,030231 tropical medicine ,Q fever ,03 medical and health sciences ,Zoonosis ,0302 clinical medicine ,[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,parasitic diseases ,Amazonian Diseases in Isolate Populations (M Nacher, Section Editor) ,medicine ,Immunology and Allergy ,[SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology ,Socioeconomics ,[SDV.MP.VIR] Life Sciences [q-bio]/Microbiology and Parasitology/Virology ,[SDV.MHEP.ME] Life Sciences [q-bio]/Human health and pathology/Emerging diseases ,0303 health sciences ,[SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases ,Suriname ,biology ,030306 microbiology ,Amazonian forest ,Coxiella burnetii ,biology.organism_classification ,medicine.disease ,Venezuela ,[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology ,3. Good health ,[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system ,French Guiana ,Infectious Diseases ,Geography ,Guiana Shield ,Latin America ,[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology ,[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,Guyana ,[SDV.MP.BAC] Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology ,[SDV.MP.PAR] Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology ,Brazil - Abstract
Purpose of Review In this review, we report on the state of knowledge about human Q fever in Brazil and on the Guiana Shield, an Amazonian region located in northeastern South America. There is a contrast between French Guiana, where the incidence of this disease is the highest in the world, and other countries where this disease is practically non-existent. Recent Findings Recent findings are essentially in French Guiana where a unique strain MST17 has been identified; it is probably more virulent than those usually found with a particularly marked pulmonary tropism, a mysterious animal reservoir, a geographical distribution that raises questions. Summary Q fever is a bacterial zoonosis due to Coxiella burnetii that has been reported worldwide. On the Guiana Shield, a region mostly covered by Amazonian forest, which encompasses the Venezuelan State of Bolivar, Guyana, Suriname, French Guiana, and the Brazilian State of Amapá, the situation is very heterogeneous. While French Guiana is the region reporting the highest incidence of this disease in the world, with a single infecting clone (MST 117) and a unique epidemiological cycle, it has hardly ever been reported in other countries in the region. This absence of cases raises many questions and is probably due to massive under-diagnosis. Studies should estimate comprehensively the true burden of this disease in the region.
- Published
- 2021
- Full Text
- View/download PDF
10. Prolactin immunoassay: does the high-dose hook effect still exist?
- Author
-
Véronique Raverot, Pauline Perrin, Philippe Chanson, Emmanuel Jouanneau, Thierry Brue, Gérald Raverot, Hospices Civils de Lyon (HCL), Laboratoire de Biologie Médicale MultiSites [Bron] (LBMMS), Hospices Civils de Lyon (HCL)-Centre de Biologie et Pathologie Est [Bron] (CBPE), Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center (CRNL), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hôpital Bicêtre, Centre de référence des maladies rares de l'hypophyse (HYPO), Service d'Endocrinologie, Diabète et Maladies Métaboliques, Université Paris-Saclay, Groupement Hospitalier Lyon-Est (GHE), Marseille medical genetics - Centre de génétique médicale de Marseille (MMG), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Marseille Maladies Rares (MarMaRa), Aix Marseille Université (AMU), Service d'endocrinologie, diabète, maladies métaboliques [Hôpital de la Conception - APHM], and Université de Lyon
- Subjects
Adenoma ,Immunoassay ,[SDV.GEN]Life Sciences [q-bio]/Genetics ,Endocrinology ,Endocrinology, Diabetes and Metabolism ,Macroprolactinoma ,Humans ,Pituitary Neoplasms ,Prolactinoma ,Hook-effect ,Prolactin - Abstract
International audience; Purpose: Measurement of prolactin in clinical laboratories is an important component in the management of patients with pituitary adenoma. Prolactin measurement is known to be sensitive to the high-dose hook effect, in the presence of extremely high prolactin concentrations. This interference is referred to in most recent articles discussing prolactin assays and the management of prolactin-secreting pituitary adenomas. The objective of our study was to evaluate if the high-dose hook effect remains relevant in current practice, when using currently available assays.Methods: Serum from a patient with a giant macroprolactinoma was assayed using all of the available prolactin assays in France in 2020, using native serum and after dilution. Technical inserts from assays were reviewed to assess the information on analytical principles, numbers of steps, and any reference to high dose hook effect.Results: Fourteen assay kits were studied by 16 laboratories; all were two-site immunometric assays, mostly using one step (11/14). Results obtained after dilution varied from 17,900 µg/L to 86,900 µg/L depending on the assay used. One tested assay was sensitive to the high-dose hook effect leading to a falsely lower prolactin concentration when measuring native serum (150 µg/L compared to 17,900 µg/L after dilution).Conclusion: The high-dose hook effect still exists in a very small minority of prolactin assays. The evolution of assay methods may lead to new assays that remain sensitive to this effect in the future. We therefore advise that the hook effect should still be mentioned in prolactin assay recommendations.
- Published
- 2022
- Full Text
- View/download PDF
11. Coronavirus Disease 2019-Associated Mucormycosis in France: A Rare but Deadly Complication
- Author
-
Danion, François, Letscher-Bru, Valérie, Guitard, Juliette, Sitbon, Karine, Dellière, Sarah, Angoulvant, Adela, Desoubeaux, Guillaume, Botterel, Francoise, Bellanger, Anne-Pauline, Gargala, Gilles, Uhel, Fabrice, Bougnoux, Marie-Elisabeth, Gerber, Victor, Michel, Justin, Cornu, Marjorie, Bretagne, Stéphane, Lanternier, Fanny, Merdji, Hamid, Delabranche, Xavier, Parrot, Antoine, Voiriot, Guillaume, Urbina, Tomas, Mebazaa, Alexandre, Chousterman, Benjamin, el Kalioubie, Ahmed, Six, Sophie, Coulon, Pauline, Sendid, Boualem, Anguel, Nadia, Damoisel, Charles, Mussini, Charlotte, Villate, Alban, Navellou, Jean-Christophe, Girault, Christophe, Cassagne, Carole, Augereau, Olivier, Dromer, Francoise, Garcia-Hermoso, Dea, Lortholary, Olivier, Alanio, Alexandre, Center of Experimental and Molecular Medicine, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg (UNISTRA), Immuno-Rhumatologie Moléculaire, Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Fédération Hospitalo-Universitaire (OMICARE), Centre de Recherche d’Immunologie et d’Hématologie [Strasbourg], CHU Strasbourg, Dynamique des interactions hôte pathogène (DIHP), Mucoviscidose: physiopathologie et phénogénomique [CRSA], Centre de Recherche Saint-Antoine (CRSA), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Mycologie moléculaire - Molecular Mycology, Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Centre National de Référence Mycoses Invasives et Antifongiques - National Reference Center Invasive Mycoses & Antifungals (CNRMA), Institut Pasteur [Paris] (IP)-Université Paris Cité (UPCité), Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), COVID-Mucor study group, Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Service de parasitologie, mycologie, médecine tropicale [CHRU Tours], Dynamic Microbiology - EA 7380 (DYNAMIC), École nationale vétérinaire - Alfort (ENVA)-Agence nationale de sécurité sanitaire de l'alimentation, de l'environnement et du travail (ANSES)-Université Paris-Est (UPE)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), CHU Henri Mondor [Créteil], Service de parasitologie et mycologie [CHRU de Besançon], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Laboratoire de Biologie Médicale de Référence Pneumopathie d'hypersensibilité, Laboratoire Chrono-environnement (UMR 6249) (LCE), Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), CHU Necker - Enfants Malades [AP-HP], Aix Marseille Université (AMU), CHU Lille, Service de Médecine Intensive et Réanimation [Strasbourg], Les Hôpitaux Universitaires de Strasbourg (HUS), CHU Tenon [AP-HP], Unité de Glycobiologie Structurale et Fonctionnelle - UMR 8576 (UGSF), Université de Lille-Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM), COVID-Mucor St Group Hamid Merdji (Médecine Intensive et Réanimation, Hôpitaux Universitaires de Strasbourg, Strasbourg, France), Xavier Delabranche (Réanimation Chirugicale, Hôpitaux Universitaires de Strasbourg, Strasbourg, France), Antoine Parrot (Service de Pneumologie, Hôpital Tenon, AP-HP, Paris, France), Guillaume Voiriot (Service de Médecine Intensive et Réanimation, Hôpital Tenon, AP-HP, Paris, France), Tomas Urbina (Service de Réanimation Médicale, Hôpital Saint Antoine, AP-HP, Paris, France), Alexandre Mebazaa (Réanimation Chirurgicale, Hôpital Saint-Louis, AP-HP, Paris, France), Benjamin Chousterman (Réanimation, Hôpital Lariboisière, AP-HP, Paris, France), Ahmed El Kalioubie (Réanimation, CHU de Lille), Sophie Six (Réanimation, CHU de Lille, Lille, France), Pauline Coulon and Boualem Sendid (Service de Mycologie, CHU de Lille, France), Nadia Anguel (Réanimation Médicale, Le Kremlin-Bicêtre, AP-HP, Paris, France), Charles Damoisel (Réanimation Polyvalente, Clamart, AP-HP, France), Charlotte Mussini (Service d’Anatomopathologie, Le Kremlin-Bicêtre, AP-HP, Paris, France), Alban Villate (Hématologie, Tours, France), Jean-Christophe Navellou (Réanimation, CHU Besançon, France), Christophe Girault (Médecine Intensive et Réanimation, CHU Rouen, France), Carole Cassagne (Laboratoire de Mycologie, CHU Timone, Marseille, France), Olivier Augereau (Laboratoire de Microbiologie, Colmar, France), Francoise Dromer, Dea Garcia-Hermoso, Olivier Lortholary, Alexandre Alanio (CNRMA, Institut Pasteur, Paris, France)., Vecteurs - Infections tropicales et méditerranéennes (VITROME), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées (IRBA), and Institut Hospitalier Universitaire Méditerranée Infection (IHU Marseille)
- Subjects
medicine.medical_specialty ,[SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases ,CAM ,Coronavirus disease 2019 (COVID-19) ,business.industry ,Brief Report ,General surgery ,Mucormycosis ,COVID-19 ,CAPA ,medicine.disease ,[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology ,mucormycosis ,AcademicSubjects/MED00290 ,Infectious Diseases ,Oncology ,[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology ,medicine ,[SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology ,business ,Complication - Abstract
We studied COVID-19 associated mucormycosis based on 17 cases reported nationwide and assessed the differences with India. They differed by frequencies of diabetes mellitus (47% in France versus up to 95% in India), hematological malignancies (35% versus 1%), anatomical sites (12% versus >80% rhino-orbito-cerebral) and prognosis (88% mortality versus, We reported 17 cases of COVID-19 associated mucormycosis in France. Compared to India, they differed by frequencies of diabetes mellitus (47% versus up to 95% in India), hematological malignancies (35% versus 1%), anatomical sites and mortality (88% versus
- Published
- 2022
- Full Text
- View/download PDF
12. Intraoperative Mapping Angiograms of the Parathyroid Glands Using Indocyanine Green During Thyroid Surgery: Results of the Fluogreen Study
- Author
-
Laurent Chiche, Fares Benmiloud, Stanislas Rebaudet, Guillaume Penaranda, Hôpital Européen de Marseille (HEM), ALPHABIO - Laboratoire de biologie médicale, Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut des sciences de la santé publique [Marseille] (ISSPAM), and Malbec, Odile
- Subjects
Adult ,Indocyanine Green ,medicine.medical_specialty ,medicine.medical_treatment ,[SDV]Life Sciences [q-bio] ,Thyroid Gland ,Thyroid Lobectomy ,Parathyroid Glands ,chemistry.chemical_compound ,medicine ,Humans ,Prospective Studies ,medicine.diagnostic_test ,business.industry ,Angiography ,Thyroidectomy ,Vascular surgery ,Surgery ,[SDV] Life Sciences [q-bio] ,medicine.anatomical_structure ,chemistry ,Cardiothoracic surgery ,Parathyroid gland ,business ,Indocyanine green ,Perfusion - Abstract
International audience; Background: During thyroid surgery, preservation of parathyroid gland (PG) feeding vessels is often impossible. The aim of the Fluogreen study was to determine the feasibility of using indocyanine green (ICG)-based intraoperative mapping angiograms of the PG (iMAP) to improve vascular preservation.Study design: This prospective study enrolled all patients undergoing thyroid lobectomy or total thyroidectomy at the Hôpital Européen Marseille between September and December 2018. After exploring the thyroid lobe by autofluorescence to locate the PGs, ICG solution was injected intravenously to locate the PG feeding vessels and guide dissection. A second ICG injection was administered at the end of the lobectomy to assess perfusion of the PGs. The primary outcome was the quality of the angiogram, scaled as iMAP 0 (not informative), iMAP 1 (general vascular pattern visible but no clear vascular pedicle flowing into the PG), or iMAP 2 (clear vascular pedicle flowing into the PG). The secondary outcome was the PG perfusion score at the end of surgery, scaled from ICG 0 (no perfusion) to ICG 2 (intense uptake).Results: A total of 47 adult patients were analyzed, including 34 total thyroidectomies and 13 lobectomies. ICG angiography assessed 76 PGs, which were scored as iMAP 2 in 24 cases (31.6%), iMAP 1 in 46 (60.5%) and iMAP 0 in six (7.9%). At the end of dissection, the ICG perfusion score was significantly better for the PGs with informative angiography (iMAP 1 or 2), than for the PGs with uninformative angiography (iMAP 0), or the PGs not evaluated by vascular angiography (p < 0.05).Conclusion: iMAP is feasible and provides direct vascular information in one-third of the cases. Further improvements to this technology are necessary, and the influence of this technique on patient outcomes during thyroidectomy will need to be further evaluated.
- Published
- 2022
- Full Text
- View/download PDF
13. Human Stool Preservation Impacts Taxonomic Profiles in 16S Metagenomics Studies
- Author
-
Anne Plauzolles, Eya Toumi, Marion Bonnet, Guillaume Pénaranda, Ghislain Bidaut, Laurent Chiche, Jérôme Allardet-Servent, Frédérique Retornaz, Benoit Goutorbe, Philippe Halfon, ALPHABIO - Laboratoire de biologie médicale, Microbes évolution phylogénie et infections (MEPHI), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hôpital Européen [Fondation Ambroise Paré - Marseille], Mathématiques et Informatique Appliquées du Génome à l'Environnement [Jouy-En-Josas] (MaIAGE), Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), and Alphabio laboratory
- Subjects
Microbiology (medical) ,preservation ,Immunology ,Microbiology ,Specimen Handling ,Feces ,16S metagenomics ,[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,RNA, Ribosomal, 16S ,microbiota ,stabilizing solution ,Humans ,[SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology ,stool ,standardization ,[SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases ,[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology ,QR1-502 ,Gastrointestinal Microbiome ,Infectious Diseases ,[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology ,Metagenome ,Metagenomics ,human gut - Abstract
International audience; Microbiotas play critical roles in human health, yet in most cases scientists lack standardized and reproducible methods from collection and preservation of samples, as well as the choice of omic analysis, up to the data processing. To date, stool sample preservation remains a source of technological bias in metagenomic sequencing, despite newly developed storage solutions. Here, we conducted a comparative study of 10 storage methods for human stool over a 14-day period of storage at fluctuating temperatures. We first compared the performance of each stabilizer with observed bacterial composition variation within the same specimen. Then, we identified the nature of the observed variations to determine which bacterial populations were more impacted by the stabilizer. We found that DNA stabilizers display various stabilizing efficacies and affect the recovered bacterial profiles thus highlighting that some solutions are more performant in preserving the true gut microbial community. Furthermore, our results showed that the bias associated with the stabilizers can be linked to the phenotypical traits of the bacterial populations present in the studied samples. Although newly developed storage solutions have improved our capacity to stabilize stool microbial content over time, they are nevertheless not devoid of biases hence requiring the implantation of standard operating procedures. Acknowledging the biases and limitations of the implemented method is key to better interpret and support true associated microbiome patterns that will then lead us towards personalized medicine, in which the microbiota profile could constitute a reliable tool for clinical practice.
- Published
- 2022
- Full Text
- View/download PDF
14. Gut microbiota in SLE: from animal models to clinical evidence and pharmacological perspectives
- Author
-
Eya Toumi, Soraya Mezouar, Anne Plauzolles, Laurent Chiche, Nathalie Bardin, Philippe Halfon, Jean Louis Mege, Microbes évolution phylogénie et infections (MEPHI), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Institut Hospitalier Universitaire Méditerranée Infection (IHU Marseille), ALPHABIO - Laboratoire de biologie médicale, Pôle Médecine Interne, Maladies Infectieuses, Hématologie [Hôpital Européen, Marseille], Hôpital Européen de Marseille (HEM), Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research (C2VN), and Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)
- Subjects
[SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases ,[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system ,Rheumatology ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology ,[SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology ,General Medicine ,[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology - Abstract
International audience; Systemic lupus erythematosus (SLE) is a multifactorial autoimmune disease driven by complex interactions between genetics and environmental factors. SLE is characterised by breaking self-immune tolerance and autoantibody production that triggers inflammation and damage of multiple organs. Given the highly heterogeneous nature of SLE, the treatments currently used are still not satisfactory with considerable side effects, and the development of new therapies is a major health issue for better patient management. In this context, mouse models significantly contribute to our knowledge of the pathogenesis of SLE and are an invaluable tool for testing novel therapeutic targets. Here, we discuss the role of the most used SLE mouse models and their contribution to therapeutic improvement. Considering the complexity of developing targeted therapies for SLE, adjuvant therapies are also increasingly proposed. Indeed, murine and human studies have recently revealed that gut microbiota is a potential target and holds great promises for successful new SLE therapies. However, the mechanisms of gut microbiota dysbiosis in SLE remain unclear to date. In this review, we propose an inventory of existing studies investigating the relationship between gut microbiota dysbiosis and SLE to establish microbiome signature that may serve as a potential biomarker of the disease and its severity as well as a new potential therapy target. This approach may open new possibilities for early diagnosis, prevention and therapeutic perspectives of SLE based on gut microbiome.
- Published
- 2023
- Full Text
- View/download PDF
15. Pseudohyponatremia: interference of hyperglycemia on indirect potentiometry
- Author
-
Charles R. Lefèvre, Charles Gibert, Laure Maucorps, Joséphine Vasse, Marie Michel, Marine Chupin, Fanny Zhao, Laurent Desmurs, Nicolas Collet, Mathilde Di Filippo, Régine Cartier, Denis Monneret, Oriane Marmontel, CarMeN, laboratoire, Laboratoire de Biologie Médicale MultiSites [Bron] (LBMMS), Hospices Civils de Lyon (HCL)-Centre de Biologie et Pathologie Est [Bron] (CBPE), Service de pharmacologie biologique et toxicologie [Rennes], Hôpital Pontchaillou-CHU Pontchaillou [Rennes], Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Université Claude Bernard Lyon 1 (UCBL), and Université de Lyon-Université de Lyon-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)
- Subjects
[SDV.AEN] Life Sciences [q-bio]/Food and Nutrition ,pseudohyponatremia ,Biochemistry (medical) ,Clinical Biochemistry ,sodium ion-selective electrode ,analytical interference ,General Medicine ,hyperglycemia ,[SDV.AEN]Life Sciences [q-bio]/Food and Nutrition - Abstract
No abstract available
- Published
- 2022
- Full Text
- View/download PDF
16. Bacterial vaginosis and other infections in pregnant women in Senegal
- Author
-
Bonneton, Marion, Huynh, Bich-Tram, Seck, Abdoulaye, Bercion, Raymond, Sarr, Fatoumata Diene, Delarocque-Astagneau, Elisabeth, Vray, Muriel, Unité d'Epidémiologie des Maladies Infectieuses, Institut Pasteur de Dakar, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP), Epidémiologie et modélisation de la résistance aux antimicrobiens - Epidemiology and modelling of bacterial escape to antimicrobials (EMAE), Institut Pasteur [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM), Unité de Bactériologie Expérimentale [Dakar, Sénégal], Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD), Laboratoire de Biologie Médicale [Dakar, Sénégal], Institut National de la Santé et de la Recherche Médicale (INSERM), Epidémiologie des Maladies Emergentes - Emerging Diseases Epidemiology, Pasteur-Cnam Risques infectieux et émergents (PACRI), Institut Pasteur [Paris]-Conservatoire National des Arts et Métiers [CNAM] (CNAM)-Institut Pasteur [Paris]-Conservatoire National des Arts et Métiers [CNAM] (CNAM), This study was financially supported by the Total Foundation, the African Center for Maternal and Child Health (Centre d’Excellence Africain pour la Santé de la Mère et de l’Enfant – CEA-SAMEF) and by the Department of International Cooperation of the Principality of Monaco., Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris Cité (UPCité)-Pasteur-Cnam Risques infectieux et émergents (PACRI), Institut Pasteur [Paris] (IP)-Conservatoire National des Arts et Métiers [CNAM] (CNAM), HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-Université Paris Cité (UPCité)-Institut Pasteur [Paris] (IP)-Conservatoire National des Arts et Métiers [CNAM] (CNAM), HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM), and Bich-Tram, Huynh
- Subjects
[SDV]Life Sciences [q-bio] ,Infectious and parasitic diseases ,RC109-216 ,Vaginal microbiome ,MESH: Vaginosis, Bacterial ,MESH: Pregnancy ,Pregnancy ,Risk Factors ,MESH: Risk Factors ,MESH: Senegal ,Humans ,MESH: Pregnancy Complications, Infectious ,Pregnancy Complications, Infectious ,MESH: Humans ,Pregnant women ,MESH: Infant, Newborn ,Infant, Newborn ,Vaginosis, Bacterial ,Bacterial vaginosis ,Senegal ,[SDV] Life Sciences [q-bio] ,MESH: Vagina ,Vagina ,Female ,MESH: Pregnant Women ,MESH: Female ,Research Article - Abstract
International audience; BackgroundBacterial vaginosis (BV) is associated with a higher risk of preterm delivery and spontaneous abortion. Yet little data on BV prevalence exist for sub-Saharan countries. The aim of this study was to estimate the prevalence of bacterial vaginosis and associated risk factors among pregnant women in Senegal.MethodsFrom October 2013 to December 2018, pregnant women in their third trimester were recruited in two primary health centers (one suburban, one rural) in Senegal. Healthcare workers interviewed women and collected a lower vaginal swab and a blood sample. Vaginal flora were classified into four categories using vaginal smear microscopic examination and Gram’s coloration. In our study, BV was defined as vaginal flora with no Lactobacillus spp. Variables associated with BV were analyzed using STATA® through univariate and multivariate analysis.ResultsA total of 457 women provided a vaginal sample for analysis. Overall, BV prevalence was 18.6% (85/457) [95% CI 15.4–22.6]) and was similar in suburban and rural areas (18.9% versus 18.1%, p = 0.843). Multivariate analysis showed that primigravidity was the only factor independently associated with a lower risk of BV (aOR 0.35 [95% CI 0.17–0.72]).ConclusionsOur study showed significant BV prevalence among pregnant women in Senegal. Although the literature has underscored the potential consequences of BV for obstetric outcomes, data are scarce on BV prevalence in sub-Saharan African countries. Before authorities consider systematic BV screening for pregnant women, a larger study would be useful in documenting prevalence, risk factors and the impact of BV on pregnancy outcomes.
- Published
- 2021
- Full Text
- View/download PDF
17. Outbreak of Cutaneous Leishmaniasis among military personnel in French Guiana, 2020: Clinical, phylogenetic, individual and environmental aspects
- Author
-
Marion Schmitt, Ghislaine Prévot, Pierre Couppié, Jean-Marie Loreau, Magalie Demar, Guillaume Frechard, Marine Ginouves, Kim M. Henry, Miguel Hernandez, Pierre-Antoine Blanc, Romain Blaizot, A. Mayet, Nathalie André, Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française], Centre d'épidémiologie et de santé publique des armées [Marseille] (CESPA), Service de Santé des Armées, Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de Référence des Leishmanioses - Laboratoire Associé de Cayenne = National Reference Centre for Cutaneous Leishmaniasis (associate laboratory) [Cayenne], Centre médico-chirurgical de Kourou [Guyane française], Laboratoire de biologie médicale [Cayenne, Guyane française] (LBM), Institut Pasteur de la Guyane, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP), Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 (CIIL), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Centre National de la Recherche Scientifique (CNRS), Université de Guyane (UG), CHU Lille, and Malbec, Odile
- Subjects
Male ,Epidemiology ,Meglumine antimoniate ,[SDV]Life Sciences [q-bio] ,RC955-962 ,Attack rate ,Disease Vectors ,Forests ,Disease Outbreaks ,Medical Conditions ,Arctic medicine. Tropical medicine ,Zoonoses ,Medicine and Health Sciences ,Medicine ,Amphotericin ,Leishmaniasis ,Phylogeny ,Data Management ,Leishmania ,Protozoans ,Ecology ,Antimicrobials ,Eukaryota ,Drugs ,Phylogenetic Analysis ,Middle Aged ,Terrestrial Environments ,French Guiana ,Phylogenetics ,[SDV] Life Sciences [q-bio] ,Military Personnel ,Infectious Diseases ,Female ,Public aspects of medicine ,RA1-1270 ,Research Article ,Neglected Tropical Diseases ,medicine.drug ,Adult ,Computer and Information Sciences ,medicine.medical_specialty ,Leishmania guyanensis ,Antiprotozoal Agents ,Leishmaniasis, Cutaneous ,Mycology ,Disease cluster ,Microbiology ,Ecosystems ,Young Adult ,Signs and Symptoms ,Cutaneous leishmaniasis ,Microbial Control ,Internal medicine ,Parasitic Diseases ,Humans ,Evolutionary Systematics ,Pentamidine ,Taxonomy ,Rainforests ,Pharmacology ,Antifungals ,Evolutionary Biology ,Miltefosine ,Protozoan Infections ,business.industry ,Ecology and Environmental Sciences ,Organisms ,Public Health, Environmental and Occupational Health ,Biology and Life Sciences ,Outbreak ,Tropical Diseases ,medicine.disease ,Parasitic Protozoans ,Insect Vectors ,Sand Flies ,Species Interactions ,Medical Risk Factors ,Lesions ,Clinical Medicine ,business - Abstract
Background Cutaneous Leishmaniasis (CL) is endemic in French Guiana but cases are usually sporadic. An outbreak signal was issued on May 15th 2020 with 15 suspected cases after a military training course in the rainforest. An outbreak investigation was carried out. Methodology/Principal findings Thirty cases were confirmed. Leishmania guyanensis was the most frequent species (90%). The most frequent presentation was ulcerative (90%). Lesions on the face and hands were frequent (40% each). Eight cases (26%) presented a poor outcome after treatment with pentamidine and required a second line with amphotericin B. Three of them required further treatments with meglumine antimoniate or miltefosine. Two spots within the training area were deemed as likely sites of contamination, due to illegal logging. The isolated Leishmania strains did not form a separate cluster. Participation in Week 13 of year 2020 was associated with infection (OR = 4.59 [1.10–19.83]; p = 0.016) while undergoing only the “Fighting” exercise was protective (OR = 0.1 [0–0.74]; p = 0.021). There was no association between infection and other risk factors at the individual level. The attack rate of Regiment B (14/105 = 13.3%) was significantly higher (OR = 4.22 [1.84–9.53], p = 0.0001) compared to Regiment A (16/507 = 3.2%). The attack rate during this training course (30/858 = 3.5%) was significantly higher (OR 2.29 [1.28–4.13]; p = 0.002) than for other missions in French Guiana during the same period (22/1427 = 1.5%). Conclusions This outbreak could be explained by a combination of factors: climatic conditions around week 13, at-risk activities including night trainings, absence of impregnation, a lesser experience of rainforest duties in Regiment B and illegal logging attracting sandflies on military training grounds., Author summary Cutaneous Leishmaniasis is caused by parasites of the Leishmania genus and infects humans after a sandfly bite. Outbreaks are rare and hard to investigate in isolated tropical areas. In this study, the authors explored the different possible origins of an outbreak of cutaneous leishmaniasis among soldiers training in the rainforest of French Guiana. The outbreak occurred in March 2020. Concerning the symptoms, several patients presented resistant infections and multiple lines of treatment, raising the issue of resistant Leishmania strains. The different strains isolated during the outbreak were not genetically closed, as far as routine PCR techniques would indicate. The authors looked for individual behaviours exposing soldiers to sandfly bites but none was significantly associated with infection. The authors found two spots in the military training areas where illegal logging probably increased the density of sandflies and put service members at risk. The 13th week of 2020 was associated to a higher risk of infection due to climatic conditions. This study shows how interactions between humans and the rainforest can increase the risk of parasitic outbreaks.
- Published
- 2021
- Full Text
- View/download PDF
18. Seroprevalence of anti-SARS-CoV-2 IgG at the first epidemic peak in French Guiana, July 2020
- Author
-
Anais Perilhou, Elodie Boizon, Dominique Rousset, Nathalie Clement, Antoine Enfissi, Véronique Servas, Didier Musso, Thierry Carage, Félix Djossou, Céline Michaud, E. Beillard, Christelle Alves Sarmento, Stephanie Eustache, Sarah Bailly, Simon Cauchemez, Jean-François Carod, Samantha James, Mélanie Gaillet, Claude Flamand, Henrik Salje, Celine Tourbillon, Institut Pasteur de la Guyane, Réseau International des Instituts Pasteur (RIIP), Modélisation mathématique des maladies infectieuses - Mathematical modelling of Infectious Diseases, Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française], Centre de Recherche Translationnelle - Center for Translational Science (CRT), Institut Pasteur [Paris], Laboratoire d'Analyses Médicales [Kourou], Eurofins Labazur, Vecteurs - Infections tropicales et méditerranéennes (VITROME), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées (IRBA), Centre Hospitalier de l'Ouest Guyanais Franck Joly [Saint-Laurent-du-Maroni, Guyane Française], Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), University of Cambridge [UK] (CAM), Johns Hopkins Bloomberg School of Public Health [Baltimore], Johns Hopkins University (JHU), This study was supported by the National Research Agency to CF, the 'European Regional Development Fund' (GY0027257) to CF, the 'Regional Health Agency of French Guiana' to CF and the « URGENCE COVID-19 » fundraising campaign of Institut Pasteur to CF., Unité d'Epidémiologie [Cayenne, Guyane française], Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP), Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Laboratoire de virologie [Cayenne, Guyane française], Laboratoire de biologie médicale [Cayenne, Guyane française] (LBM), Institut Pasteur [Paris] (IP)-Université Paris Cité (UPCité), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées [Brétigny-sur-Orge] (IRBA), This study was supported by the National Research Agency to CF, the 'European Regional Development Fund' (GY0027257) to CF, the 'Regional Health Agency of French Guiana' to CF and the « URGENCE COVID-19 » fundraising campaign of Institut Pasteur to CF. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript, We are grateful to all field workers, collaborators, technical and medical staff from Health Centers Department of Cayenne Hospital Center and biological laboratories and health centers involved in the EPI-COVID-19 project. We thank Bhety LABEAU, David MOUA, Laetitia BREMAND, Sylvie ALOEPOE, Elisabeth CHAN from Institut Pasteur in French Guiana, Nathalie JOLLY from Clinical Core of the Center for Translational Research of Institut Pasteur. We also thank Sophie GAULIN, Lysiane ROMAIN, Véronique TOGNERI and Tadens MPWENE from La Liberté., ANR-20-COVI-0014,EPI-COVID-19,Étude de la transmission intra-ménage autour des cas confirmés de COVID-19 en Guyane(2020), Flamand, Claude [0000-0002-8064-445X], Beillard, Emmanuel [0000-0002-2546-7614], Michaud, Céline [0000-0001-5410-6298], Cauchemez, Simon [0000-0001-9186-4549], Apollo - University of Cambridge Repository, and Salje, Henrik [0000-0003-3626-4254]
- Subjects
RNA viruses ,Viral Diseases ,Pulmonology ,Coronaviruses ,Physiology ,RC955-962 ,030204 cardiovascular system & hematology ,Antibodies, Viral ,Serology ,MESH: Aged, 80 and over ,Medical Conditions ,0302 clinical medicine ,Seroepidemiologic Studies ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,Arctic medicine. Tropical medicine ,MESH: Child ,Pandemic ,MESH: COVID-19 ,Medicine ,030212 general & internal medicine ,[MATH]Mathematics [math] ,Enzyme-Linked Immunoassays ,Child ,Pathology and laboratory medicine ,Virus Testing ,MESH: Immunoglobulin G ,MESH: Aged ,Aged, 80 and over ,[SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases ,MESH: Middle Aged ,Medical microbiology ,Middle Aged ,MESH: Infant ,French Guiana ,3. Good health ,Bioassays and Physiological Analysis ,Infectious Diseases ,Physiological Parameters ,MESH: Young Adult ,Child, Preschool ,Viruses ,Public aspects of medicine ,RA1-1270 ,SARS CoV 2 ,Pathogens ,Research Article ,Adult ,SARS coronavirus ,Adolescent ,Coronavirus disease 2019 (COVID-19) ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Research and Analysis Methods ,Microbiology ,Respiratory Disorders ,Young Adult ,03 medical and health sciences ,MESH: Cross-Sectional Studies ,Diagnostic Medicine ,MESH: French Guiana ,Humans ,Seroprevalence ,MESH: SARS-CoV-2 ,Immunoassays ,Enzyme Assays ,Aged ,MESH: Adolescent ,Medicine and health sciences ,MESH: Humans ,MESH: Seroepidemiologic Studies ,Routine screening ,Biology and life sciences ,SARS-CoV-2 ,business.industry ,MESH: Child, Preschool ,Body Weight ,Organisms ,Viral pathogens ,Public Health, Environmental and Occupational Health ,COVID-19 ,Infant ,Spike Protein ,MESH: Adult ,Covid 19 ,Microbial pathogens ,Cross-Sectional Studies ,Young population ,Immunoglobulin G ,Respiratory Infections ,Immunologic Techniques ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,Biochemical Analysis ,business ,MESH: Antibodies, Viral ,Demography - Abstract
Background While Latin America has been heavily affected by the pandemic, only a few seroprevalence studies have been conducted there during the first epidemic wave in the first half of 2020. Methodology/Principal findings A cross-sectional survey was performed between 15 July 2020 and 23 July 2020 among individuals who visited 4 medical laboratories or 5 health centers for routine screening or clinical management, with the exception of symptomatic suggestive cases of covid-19. Samples were screened for the presence of anti-SARS-CoV-2 IgG directed against domain S1 of the SARS-CoV-2 spike protein using the anti-SARS-CoV-2 enzyme-linked immunosorbent assay (ELISA) from Euroimmun. Conclusions/Significance The overall seroprevalence was 15.4% [9.3%-24.4%] among 480 participants, ranging from 4.0% to 25.5% across the different municipalities. The seroprevalence did not differ according to gender (p = 0.19) or age (p = 0.51). Among SARS-CoV-2 positive individuals, we found that 24.6% [11.5%-45.2%] reported symptoms consistent with COVID-19. Our findings revealed high levels of infection across the territory but a low number of resulting deaths, which can be explained by French Guiana’s young population structure., Author summary While Latin America has been heavily affected by the pandemic, only a few seroprevalence studies have been conducted there during the first epidemic wave in the first half of 2020. A cross-sectional survey was performed between 15 July 2020 and 23 July 2020 among individuals who visited 4 medical laboratories or 5 health centers for routine screening or clinical management, with the exception of symptomatic suggestive cases of covid-19. Samples were screened for the presence of anti-SARS-CoV-2 IgG using the anti-SARS-CoV-2 enzyme-linked immunosorbent assay (ELISA) from Euroimmun. The overall seroprevalence was 15.4% [9.3%-24.4%] among 480 participants, ranging from 4.0% to 25.5% across the different municipalities. The seroprevalence did not differ according to gender (p = 0.19) or age (p = 0.51). Among SARS-CoV-2 positive individuals, we found that 24.6% [11.5%-45.2%] reported symptoms consistent with COVID-19. Our findings revealed high levels of infection across the territory but a low number of resulting deaths, which can be explained by French Guiana’s young population structure.
- Published
- 2021
- Full Text
- View/download PDF
19. Population Genetic Structure and Isolation by Distance of Helicobacter pylori in Senegal and Madagascar
- Author
-
Jean-Michel Thiberge, Josette Raymond, Benoit Garin, Rado Manitrala Ramanampamonjy, Bodo Linz, D. Dia, Sébastien Breurec, Jean-François Carod, Abdoulaye Seck, Clairette Romaine Raharisolo Vololonantenainab, Department of Biochemistry and Molecular Biology, Pennsylvania State University (Penn State), Penn State System-Penn State System, Laboratoire d’Anatomie et de Cytologie Pathologiques, Institut Pasteur de Madagascar, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP), Laboratoire de Biologie Médicale [Dakar, Sénégal], Institut Pasteur de Dakar, Centre de Biologie Clinique [Antananarivo] (IPM), Département de Gastro-entérologie, Centre Hospitaler Le Dantec, Unité de Bactériologie Expérimentale [Antananarivo, Madagascar] (IPM), Centre Hospitalier Universitaire Joseph Ravoahangy Befelatanana, Génotypage des Pathogènes et Santé Publique (Plate-forme) (PF8), Institut Pasteur [Paris], Pathogenèse de Helicobacter, Laboratoire de Biologie médicale, Institut Pasteur de Bangui, This study was supported by grants from Institut Pasteur (ACIP Helicobacter pylori) and the ERA-NET PathoGenoMics (project HELDIVNET, decision n°ANR-06-PATHO-007-01)., and Institut Pasteur [Paris] (IP)
- Subjects
lcsh:Medicine ,Population genetics ,0302 clinical medicine ,Gram Negative ,Genome Sequencing ,lcsh:Science ,Phylogeny ,Helicobacter pylori/isolation & purification ,Helicobacter Infections/microbiology ,Aged, 80 and over ,2. Zero hunger ,Genetics ,0303 health sciences ,education.field_of_study ,Multidisciplinary ,Geography ,Population Groups/genetics ,Genomics ,Middle Aged ,Helicobacter pylori/genetics ,Senegal ,Bacterial Pathogens ,[SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitology ,Genetic Variation/genetics ,Genetic structure ,Medicine ,030211 gastroenterology & hepatology ,Genetic isolate ,Research Article ,Adult ,Adolescent ,Human Migration ,Population ,Black People ,Zoology ,Gastroenterology and Hepatology ,Biology ,Human Geography ,Southeast asian ,Microbiology ,Helicobacter Infections ,Helicobacter Infections/genetics ,Young Adult ,03 medical and health sciences ,Population Groups ,Genetic variation ,Madagascar ,Humans ,education ,GeneticsPopulation/methods ,Aged ,030304 developmental biology ,Isolation by distance ,Evolutionary Biology ,Genetic diversity ,Helicobacter pylori ,lcsh:R ,Genetic Variation ,African Continental Ancestry Group/genetics ,Endoscopy ,Organismal Evolution ,Genetics, Population ,Aged 80 and over ,Microbial Evolution ,Earth Sciences ,lcsh:Q ,Population Genetics ,Geography/methods - Abstract
International audience; Helicobacter pylori has probably infected the human stomach since our origins and subsequently diversified in parallel with their human hosts. The genetic population history of H. pylori can therefore be used as a marker for human migration. We analysed seven housekeeping gene sequences of H. pylori strains isolated from 78 Senegalese and 24 Malagasy patients and compared them with the sequences of strains from other geographical locations. H. pylori from Senegal and Madagascar can be placed in the previously described HpAfrica1 genetic population, subpopulations hspWAfrica and hspSAfrica, respectively. These 2 subpopulations correspond to the distribution of Niger-Congo speakers in West and most of subequatorial Africa (due to Bantu migrations), respectively. H. pylori appears as a single population in Senegal, indicating a long common history between ethnicities as well as frequent local admixtures. The lack of differentiation between these isolates and an increasing genetic differentiation with geographical distance between sampling locations in Africa was evidence for genetic isolation by distance. The Austronesian expansion that started from Taiwan 5000 years ago dispersed one of the 10 subgroups of the Austronesian language family via insular Southeast Asia into the Pacific and Madagascar, and hspMaori is a marker for the entire Austronesian expansion. Strain competition and replacement of hspMaori by hpAfrica1 strains from Bantu migrants are the probable reasons for the presence of hspSAfrica strains in Malagasy of Southeast Asian descent. hpAfrica1 strains appear to be generalist strains that have the necessary genetic diversity to efficiently colonise a wide host spectrum.
- Published
- 2014
- Full Text
- View/download PDF
20. Performances, feasibility and acceptability of nasopharyngeal swab, saliva and oral-self sampling swab for the detection of severe acute respiratory syndrome coronavirus 2
- Author
-
Audrey Mérens, Christophe Renard, Anne Margaux Legland, Julie Plantamura, Olivier Bylicki, Marie Pierre Otto, Eric Garnotel, Aurore Bousquet, Frédéric Janvier, Hervé Delacour, Elodie Valero, Christine Bigaillon, Vincent Foissaud, P. Vest, Catherine Verret, Solenne Martin, Hélène Astier, Laboratoire de Microbiologie [Hôpital d'Instruction des Armées Bégin, Saint-Mandé] (Service de Santé des Armées), Hôpital d'Instruction des Armées Bégin [Saint-Mandé, France], Hopital d'instruction des armées Sainte-Anne [Toulon] (HIA), Service de Santé des Armées, École du Val de Grâce (EVDG), French Military Health Service Academy, Vecteurs - Infections tropicales et méditerranéennes (VITROME), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées [Brétigny-sur-Orge] (IRBA), Hôpital d'Instruction des Armées Laveran, Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Laboratoire de biologie médicale, and Service de Santé des Armées-Hôpital d'instruction des Armées Percy
- Subjects
0301 basic medicine ,Microbiology (medical) ,medicine.medical_specialty ,2019-20 coronavirus outbreak ,Saliva ,Coronavirus disease 2019 (COVID-19) ,Hospitalized patients ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,030106 microbiology ,03 medical and health sciences ,0302 clinical medicine ,[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,Internal medicine ,Medicine ,Sampling (medicine) ,[SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology ,030212 general & internal medicine ,ComputingMilieux_MISCELLANEOUS ,[SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases ,business.industry ,General Medicine ,[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology ,Infectious Diseases ,Multicenter study ,[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology ,business ,Self sampling - Abstract
Molecular diagnosis on nasopharyngeal swabs (NPS) is the current standard for COVID-19 diagnosis, but saliva may be an alternative specimen to facilitate access to diagnosis. We compared analytic performances, feasibility and acceptability of NPS, saliva, and oral-self sampling swab for the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A prospective, multicenter study was conducted in military hospitals in France among adult outpatients attending COVID-19 diagnosis centers or hospitalized patients. For each patient, all samples were obtained and analyzed simultaneously with RT-PCR or transcription-mediated amplification method. Clinical signs, feasibility, and acceptability for each type of sample were collected. A total of 1220 patients were included, corresponding to 1205 NPS and saliva and 771 OS. Compared to NPS, the sensitivity, specificity, and kappa coefficient for tests performed on saliva were 87.8% (95% CI 83.3-92.3), 97.1% (95% CI 96.1-98.1), and 0.84 (95% CI 0.80-0.88). Analytical performances were better in symptomatic patients. Ct values were significantly lower in NPS than saliva. For OS, sensitivity was estimated to be 61.1% (95% CI 52.7-69.4) and Kappa coefficient to be 0.69 (95% CI 0.62-0.76). OS was the technique preferred by the patients (44.3%) before saliva (42.4%) and NPS (13.4%). Instructions were perceived as simple by patients (> 90%) for saliva and OS. Finally, the painful nature was estimated to be 0.9 for OS, on a scale from 0 to 10, and to be 5.3 for NPS. Performances of OS are not sufficient. Saliva is an acceptable alternative to NPS for symptomatic patient but the process required additional steps to fluidize the sample.
- Published
- 2021
- Full Text
- View/download PDF
21. 3-methylhistidine and clinical outcomes in maintenance haemodialysis patients
- Author
-
Emilie Bres, Cécile Pagan, Anaïs Bouchara, Myriam Pastural, Samuel Granjon, Maurice Laville, Denis Fouque, Christophe O Soulage, Laetitia Koppe, Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), Laboratoire de Biologie Médicale MultiSites [Bron] (LBMMS), Hospices Civils de Lyon (HCL)-Centre de Biologie et Pathologie Est [Bron] (CBPE), Association pour l'Utilisation du Rein Artificiel Région Lyonnaise [Lyon] (AURAL), Cerballiance, and CarMeN, laboratoire
- Subjects
Transplantation ,[SDV]Life Sciences [q-bio] ,Methylhistidines ,mortality ,Actins ,[SDV] Life Sciences [q-bio] ,cardiovascular events ,3-methylhistidine ,maintenance hemodialysis ,Nephrology ,Renal Dialysis ,Creatinine ,lean tissue mass ,Humans ,Kidney Failure, Chronic ,Biomarkers ,Serum Albumin - Abstract
Background Chronic kidney disease is an important contributor to morbidity and mortality. 3-methylhistidine (3-MH) is the by-product of actin and myosin degradation reflecting skeletal muscle turnover. Markedly elevated 3-MH levels have been documented in uraemic patients, but the interpretation of high 3-MH concentration in maintenance haemodialysis (MHD) patients remains unclear. Indeed, it is not known whether elevated serum 3-MH levels are a marker of excessive muscle catabolism or a better lean tissue mass. Here, we evaluated the association between serum 3-MH levels and clinical outcomes in these patients. Methods Serum 3-MH concentration was measured by reverse-phase liquid chromatography/tandem mass spectrometry in a cohort of MHD patients. We analysed the relationships between various clinical/laboratory indices, lean tissue mass measured by bioimpedance spectroscopy, mortality and cardiovascular (CV) events. Results Serum 3-MH concentration was positively correlated with serum albumin, normalized protein catabolic rate (nPCR), simplified creatinine index (SCI) and lean tissue mass. Of 291 MHD patients, during a mean follow-up of 847 days, 91 patients died and 101 patients experienced a CV event. Survival was significantly better in patients with high 3-MH concentrations (P = .002). A higher level of 3-MH was also associated with a lower CV mortality and lower incidence of CV events (P = .015 and P Conclusion Elevated serum 3-MH concentration appears to be a marker of better lean tissue mass and nutritional status. Low serum 3-MH is a robust and independent predictor of CV events in the MHD population.
- Published
- 2021
- Full Text
- View/download PDF
22. Severe bacterial neonatal infections in Madagascar, Senegal, and Cambodia: A multicentric community-based cohort study
- Author
-
Bich-Tram, Huynh, Elsa, Kermorvant-Duchemin, Rattanak, Chheang, Frederique, Randrianirina, Abdoulaye, Seck, Elisoa, Hariniaina Ratsima, Zafitsara Zo, Andrianirina, Jean-Baptiste, Diouf, Armya Youssouf, Abdou, Sophie, Goyet, Véronique, Ngo, Siyin, Lach, Long, Pring, Touch, Sok, Michael, Padget, Fatoumata Diene, Sarr, Laurence, Borand, Benoit, Garin, Jean-Marc, Collard, Perlinot, Herindrainy, Agathe, de Lauzanne, Muriel, Vray, Elisabeth, Delarocque-Astagneau, Didier, Guillemot, Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Epidémiologie et modélisation de la résistance aux antimicrobiens - Epidemiology and modelling of bacterial escape to antimicrobials (EMAE), Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Unité de biologie médicale - Medical biology unit [Phnom Penh, Cambodia], Institut Pasteur du Cambodge, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP), Centre de Biologie Clinique [Antananarivo] (IPM), Institut Pasteur de Madagascar, Laboratoire de Biologie Médicale [Dakar, Sénégal], Institut Pasteur de Dakar, Centre Hospitalier de Soavinandriana (CENHOSOA), Centre Hospitalier Roi Baudouin, Unité d'Épidémiologie et de Santé Publique [Phnom Penh], Ministry of Health [Phnom Penh], Unité d'Epidémiologie des Maladies Infectieuses, Unité de Bactériologie Expérimentale [Antananarivo, Madagascar] (IPM), Unité d'Epidémiologie [Antananarivo, Madagascar] (IPM), This work was supported by the Department of International Cooperation of the Principality of Monaco, MSDAVENIR and Total foundation., We also thank the Department of International Affairs and the Centre de Recherche Translationnelle - Coordination Clinique of Institut Pasteur for their support in the management of the study., Bich-Tram, Huynh, and Institut Pasteur [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM)
- Subjects
Adult ,Male ,Bacterial Diseases ,Asia ,Adolescent ,Economics ,Physiology ,Maternal Health ,[SDV]Life Sciences [q-bio] ,Social Sciences ,Economic Geography ,Infant, Newborn, Diseases ,Cohort Studies ,Geographical Locations ,Young Adult ,Labor and Delivery ,Medical Conditions ,Pregnancy ,Madagascar ,Medicine and Health Sciences ,Humans ,Birth Weight ,Prospective Studies ,Geography ,Incidence ,Body Weight ,Infant, Newborn ,Patient Acuity ,Biology and Life Sciences ,Neonates ,Obstetrics and Gynecology ,Bacterial Infections ,Middle Aged ,Senegal ,[SDV] Life Sciences [q-bio] ,Infectious Diseases ,Physiological Parameters ,People and Places ,Africa ,Earth Sciences ,Birth ,Low and Middle Income Countries ,Women's Health ,Female ,Cambodia ,Research Article ,Developmental Biology - Abstract
Background Severe bacterial infections (SBIs) are a leading cause of neonatal deaths in low- and middle-income countries (LMICs). However, most data came from hospitals, which do not include neonates who did not seek care or were treated outside the hospital. Studies from the community are scarce, and few among those available were conducted with high-quality microbiological techniques. The burden of SBI at the community level is therefore largely unknown. We aimed here to describe the incidence, etiology, risk factors, and antibiotic resistance profiles of community-acquired neonatal SBI in 3 LMICs. Methods and findings The BIRDY study is a prospective multicentric community-based mother and child cohort study and was conducted in both urban and rural areas in Madagascar (2012 to 2018), Cambodia (2014 to 2018), and Senegal (2014 to 2018). All pregnant women within a geographically defined population were identified and enrolled. Their neonates were actively followed from birth to 28 days to document all episodes of SBI. A total of 3,858 pregnant women (2,273 (58.9%) in Madagascar, 814 (21.1%) in Cambodia, and 771 (20.0%) in Senegal) were enrolled in the study, and, of these, 31.2% were primigravidae. Women enrolled in the urban sites represented 39.6% (900/2,273), 45.5% (370/814), and 61.9% (477/771), and those enrolled in the rural sites represented 60.4% (1,373/2,273), 54.5% (444/814), and 38.1% (294/771) of the total in Madagascar, Cambodia, and Senegal, respectively. Among the 3,688 recruited newborns, 49.6% were male and 8.7% were low birth weight (LBW). The incidence of possible severe bacterial infection (pSBI; clinical diagnosis based on WHO guidelines of the Integrated Management of Childhood Illness) was 196.3 [95% confidence interval (CI) 176.5 to 218.2], 110.1 [88.3 to 137.3], and 78.3 [59.5 to 103] per 1,000 live births in Madagascar, Cambodia, and Senegal, respectively. The incidence of pSBI differed between urban and rural sites in all study countries. In Madagascar, we estimated an incidence of 161.0 pSBI per 1,000 live births [133.5 to 194] in the urban site and 219.0 [192.6 to 249.1] pSBI per 1,000 live births in the rural site (p = 0.008). In Cambodia, estimated incidences were 141.1 [105.4 to 189.0] and 85.3 [61.0 to 119.4] pSBI per 1,000 live births in urban and rural sites, respectively (p = 0.025), while in Senegal, we estimated 103.6 [76.0 to 141.2] pSBI and 41.5 [23.0 to 75.0] pSBI per 1,000 live births in urban and rural sites, respectively (p = 0.006). The incidences of culture-confirmed SBI were 15.2 [10.6 to 21.8], 6.5 [2.7 to 15.6], and 10.2 [4.8 to 21.3] per 1,000 live births in Madagascar, Cambodia, and Senegal, respectively, with no difference between urban and rural sites in each country. The great majority of early-onset infections occurred during the first 3 days of life (72.7%). The 3 main pathogens isolated were Klebsiella spp. (11/45, 24.4%), Escherichia coli (10/45, 22.2%), and Staphylococcus spp. (11/45, 24.4%). Among the 13 gram-positive isolates, 5 were resistant to gentamicin, and, among the 29 gram-negative isolates, 13 were resistant to gentamicin, with only 1 E. coli out of 10 sensitive to ampicillin. Almost one-third of the isolates were resistant to both first-line drugs recommended for the management of neonatal sepsis (ampicillin and gentamicin). Overall, 38 deaths occurred among neonates with SBI (possible and culture-confirmed SBI together). LBW and foul-smelling amniotic fluid at delivery were common risk factors for early pSBI in all 3 countries. A main limitation of the study was the lack of samples from a significant proportion of infants with pBSI including 35 neonatal deaths. Without these samples, bacterial infection and resistance profiles could not be confirmed. Conclusions In this study, we observed a high incidence of neonatal SBI, particularly in the first 3 days of life, in the community of 3 LMICs. The current treatment for the management of neonatal infection is hindered by antimicrobial resistance. Our findings suggest that microbiological diagnosis of SBI remains a challenge in these settings and support more research on causes of neonatal death and the implementation of early interventions (e.g., follow-up of at-risk newborns during the first days of life) to decrease the burden of neonatal SBI and associated mortality and help achieve Sustainable Development Goal 3., In a community-based, prospective cohort study, Bich-Tram Huynh and colleagues investigate the incidence and factors associated with several bacterial infections among neonates in rural and urban areas of three low-middle income countries., Author summary Why was this study done? Severe bacterial infections (SBIs) are a leading cause of neonatal deaths in low- and middle-income countries (LMICs). In LMICs, most data come from studies conducted in hospitals. However, a significant proportion of neonates do not have access to the hospital or die before reaching it in these countries. The magnitude of SBI and its causative pathogens, consequences, and risk factors at the community level remain largely unknown in LMICs. What did the researchers do and find? We conducted a prospective multicentric, rural and urban, community-based mother and child cohort study in Madagascar, Cambodia, and Senegal. All pregnant women within a geographically defined population were identified and invited to participate. Their neonates were actively followed from birth to 28 days. Among the 3,688 recruited newborns, 514 neonates presented an episode of SBI, with the great majority occurring during the first 3 days of life (54.7%). The incidence of possible severe bacterial infection (pSBI) varied from 78.3 [95% confidence interval [CI] 59.5 to 103] to 196.3 [176.5 to 218.2] cases per 1,000 live births and was the highest in Madagascar; the incidence of confirmed severe bacterial infection (cSBI) varied from 6.5 [2.7 to 15.6] to 15.2 [10.6 to 21.8] per 1,000 live births. The 3 main pathogens isolated were Klebsiella spp. (24.4%), Escherichia coli (22.2%), and Staphylococcus spp. (26.7%). Almost one-third of the isolates (31%) were resistant to both first-line drugs recommended by WHO for the management of neonatal sepsis. What do these findings mean? Our findings show the high burden of neonatal SBI, particularly in the first 3 days of life, in the community of 3 LMICs in Asia and Africa. These findings also suggest that the current treatment strategy for the management of neonatal infection may be hindered by antimicrobial resistance. Our findings support the implementation of early interventions (e.g., follow-up of at-risk newborns during the first days of life) to decrease the burden of severe neonatal infection and mortality and help achieve Sustainable Development Goal 3.
- Published
- 2021
- Full Text
- View/download PDF
23. Factors associated with SARS-CoV2 infection and care pathways among the most vulnerable populations living in Marseille: a case control study
- Author
-
Ismaïl Alsaïdi, Frédéric De Sousa Santos, Bérangère Plard, Elise Janvier, Aurélie Tinland, Abdelmajid Hafni, Emilie Mosnier, Aix Marseille Université (AMU), Hôpital de la Timone [CHU - APHM] (TIMONE), Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut des sciences de la santé publique [Marseille] (ISSPAM), Association d'Aide Aux Jeunes Travailleurs [Marseille] (AAJT), Centre d'études et de recherche sur les services de santé et la qualité de vie (CEReSS), ALPHABIO - Laboratoire de biologie médicale, Centre Hospitalier Alès-Cévennes (CHAC), and Malbec, Odile
- Subjects
Adult ,Male ,SARS-CoV-2 ,Healthcare disparities ,[SDV]Life Sciences [q-bio] ,Vulnerable populations ,COVID-19 ,Healthcare delivery ,3. Good health ,[SDV] Life Sciences [q-bio] ,Young Adult ,Social determinants of health ,Risk factors ,Case-Control Studies ,Humans ,RNA, Viral ,Female ,Public aspects of medicine ,RA1-1270 ,Pandemics ,Research Article - Abstract
Background The Covid-19 pandemic has led to substantial and unexpected increases in morbidity and mortality in France. Vulnerable populations housed in accommodation centres have a greater risk of infection because collective housing and their dependence on social support services mean it is more difficult to apply preventive measures. They are also at greater risk of developing severe forms of Covid-19 and waiting longer before seeking healthcare (for Covid-19 or other) treatment. We aimed to identify the factors associated with SARS-CoV2 infection in the most vulnerable populations in the city of Marseille. Methods The study sample comprised users of various services provided by the association AAJT in Marseille, France, some presenting symptoms suggestive of Covid-19 and others not. All had routine health surveillance provided by AAJT’s dedicated healthcare team between March 2020 and May 2020. Using univariate and multivariate analyses, we studied the influence of several variables on morbidity associated with Covid-19. Results The study included 64 participants, 29 of whom tested positive for Covid-19 and 35 control subjects. Median age was 21.16 years old. Individuals in the ‘Covid-19 case’ group (p
- Published
- 2021
- Full Text
- View/download PDF
24. Clinical Features of Mycobacterium canettii Infection: A Retrospective Study of 20 Cases Among French Soldiers and Relatives
- Author
-
Michel Fabre, Frédéric Rivière, Charles Soler, Jean-Baptiste Roseau, Emilie Javelle, Marc Aletti, Fabrice Simon, Anaïs Briquet, Nicolas Cazes, Rithy Vong, S. Duron, Marie-Pierre Otto, Cécile Ficko, Christine Pourcel, Département de Pneumologie, Centre Hospitalier Sainte Anne, Vecteurs - Infections tropicales et méditerranéennes (VITROME), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées [Brétigny-sur-Orge] (IRBA), Service de Santé des Armées, CHU CLAMART, Laboratoire de biologie médicale, Service de Santé des Armées-Hôpital d'instruction des Armées Percy, Hôpital d'Instruction des Armées Begin, Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre d'épidémiologie et de santé publique des armées [Marseille] (CESPA), Centre de recherche en éducation de Nantes (CREN), Le Mans Université (UM)-Université de Nantes - UFR Lettres et Langages (UFRLL), Université de Nantes (UN)-Université de Nantes (UN), Institut de Biologie Intégrative de la Cellule (I2BC), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS), Département Biologie des Génomes (DBG), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS), Hôpital d'instruction des Armées Percy, Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées (IRBA), Université de Nantes - UFR Lettres et Langages (UFRLL), Université de Nantes (UN)-Université de Nantes (UN)-Le Mans Université (UM), and SERRE, Marie-Claude
- Subjects
Adult ,Male ,0301 basic medicine ,Microbiology (medical) ,medicine.medical_specialty ,Pediatrics ,Tuberculosis ,Adolescent ,[SDV]Life Sciences [q-bio] ,030106 microbiology ,Mycobacterium ,Young Adult ,03 medical and health sciences ,Epidemiology ,medicine ,Humans ,Child ,Immunodeficiency ,Retrospective Studies ,Mycobacterium Infections ,biology ,business.industry ,Public health ,Infant ,Retrospective cohort study ,Adenitis ,Middle Aged ,medicine.disease ,biology.organism_classification ,3. Good health ,[SDV] Life Sciences [q-bio] ,Military personnel ,Military Personnel ,030104 developmental biology ,Infectious Diseases ,Mycobacterium tuberculosis complex ,Child, Preschool ,Female ,business - Abstract
Background Mycobacterium canettii forms part of the Mycobacterium tuberculosis complex. Mycobacterium canettii infections are mainly described in the Horn of Africa. The permanent presence of French soldiers in Djibouti raises the question of the risk of being infected with M. canettii. Here, we describe M. canettii infections among French military and their families between 1998 and 2015. Methods This retrospective study relied on 3 sources of data: the reference center for mycobacteria in the Biology Department at Percy Military Hospital in Paris, the French Military Center for Epidemiology and Public Health, and the scientific literature. After an exhaustive census of the strains, we studied the epidemiological data on 20 cases among French soldiers and their families. Results Twenty cases of M. canettii infections are reported, including 5 unpublished cases. Adenitis predominates (n = 15), especially in the cervico facial area and among children; 1 case was observed 1 month after dental care in Djibouti. The pulmonary forms were less frequent (n = 6), and 3 atypical forms are described. All patients had stayed in Djibouti. Conclusions Cases of M. canettii infection among the French military consisted mainly of adenitis; disseminated forms were possible with immunodeficiency. Their evolution under specific treatments was comparable to that of tuberculosis. The presumed origin of the infection seemed to be environmental, possibly a water reservoir, and not due to human-to-human contagion.
- Published
- 2019
- Full Text
- View/download PDF
25. Shallow Shotgun Metagenomics as a cost-effective and accurate alternative to WGS for taxonomic profiling and clinical diagnosis
- Author
-
Goutorbe, Benoit, Abraham, Anne-Laure, Mariadassou, Mahendra, Plauzolles, Anne, Bidaut, Ghislain, Halfon, Philippe, Schbath, Sophie, Mathématiques et Informatique Appliquées du Génome à l'Environnement [Jouy-En-Josas] (MaIAGE), Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Laboratoire Alphabio, ALPHABIO - Laboratoire de biologie médicale, Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Abraham, Anne-Laure, Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Aix Marseille Université (AMU), and SCHBATH, Sophie
- Subjects
[SDV.BIBS] Life Sciences [q-bio]/Quantitative Methods [q-bio.QM] ,[SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitology ,Shallow shotgun metagenomics ,Sequencing depth ,Gut microbiota ,[INFO.INFO-BI]Computer Science [cs]/Bioinformatics [q-bio.QM] ,[SDV.MP] Life Sciences [q-bio]/Microbiology and Parasitology ,[SDV.BIBS]Life Sciences [q-bio]/Quantitative Methods [q-bio.QM] ,[INFO.INFO-BI] Computer Science [cs]/Bioinformatics [q-bio.QM] ,Clinical research - Abstract
International audience; Shallow shotgun metagenomics has been recently suggested as a promising strategy to study human microbiota, providing nearly identical taxonomic profiles than deep shotgun metagenomics with a sequencing cost similar to metabarcoding. With shallow sequencing approach (typically
- Published
- 2021
26. Online self-sampling kits to screen multipartner MSM for HIV and other STIs: Participant characteristics and factors associated with kit use in the first three months of the MemoDepistages program, France, 2018
- Author
-
Rahib, Delphine, Delagreverie, Héloïse, Gabassi, Audrey, Le Thi, Thuy, Vassel, Eléonore, Vodosin, Pierre, Leveau, Benjamin, Pisoni, Amandine, Tuaillon, Edouard, Digne, Julien, Icard, Vinca, Delaugerre, Constance, Lydié, Nathalie, Santé publique France - French National Public Health Agency [Saint-Maurice, France], Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), INSERM U944 Laboratoire de Pathologie et Virologie Moléculaire, Laboratoire de Pathologie et Virologie Moléculaire, Laboratoire de Virologie [CHU Saint-Louis], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre de Biologie et Pathologie Nord [Hôpital de la Croix-Rousse, CHU-HCL], Laboratoire de Virologie [CHRU Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), ALPHABIO - Laboratoire de biologie médicale, Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), and Rahib, Delphine
- Subjects
[SDV] Life Sciences [q-bio] ,[SDV]Life Sciences [q-bio] ,Screening ,men ,Service delivery ,ComputingMilieux_MISCELLANEOUS - Abstract
International audience
- Published
- 2021
- Full Text
- View/download PDF
27. Major discrepancy between factual antibiotic resistance and consumption in South of France: analysis of 539,037 bacterial strains
- Author
-
Ousmane Oumou Diallo, Sophie Alexandra Baron, Gregory Dubourg, Hervé Chaudet, Philippe Halfon, Sabine Camiade, Béatrice Comte, Stéphanie Joubert, Arnaud François, Philippe Seyral, François Parisot, Jean-Paul Casalta, Raymond Ruimy, Christophe Maruejouls, Jean-Christophe Achiardy, Sophie Burignat, Joseph Carvajal, Edouard Delaunay, Sandra Meyer, Pierre-Yves Levy, Patricia Roussellier, Patrick Brunet, Claude Bosi, Philippe Stolidi, Jean-Pierre Arzouni, Gisele Gay, Pierre Hance, Philippe Colson, Didier Raoult, Jean-Marc Rolain, Microbes évolution phylogénie et infections (MEPHI), Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU), Institut Hospitalier Universitaire Méditerranée Infection (IHU Marseille), Vecteurs - Infections tropicales et méditerranéennes (VITROME), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées (IRBA), ALPHABIO - Laboratoire de biologie médicale, Equipe de Recherche sur les Rationalités Philosophiques et les Savoirs (ERRAPHIS), Université Toulouse - Jean Jaurès (UT2J), Eurofins Labazur, European Organisation for the Exploitation of Meteorological Satellites (EUMETSAT), Centre Hospitalier Universitaire de Nice (CHU Nice), Hôpital de la Timone [CHU - APHM] (TIMONE), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées [Brétigny-sur-Orge] (IRBA), and Université de Toulouse (UT)-Université de Toulouse (UT)
- Subjects
0301 basic medicine ,Acinetobacter baumannii ,Veterinary medicine ,Imipenem ,Staphylococcus aureus ,Databases, Factual ,medicine.drug_class ,Science ,[SDV]Life Sciences [q-bio] ,030106 microbiology ,Antibiotics ,Microbial Sensitivity Tests ,medicine.disease_cause ,Article ,03 medical and health sciences ,0302 clinical medicine ,Antibiotic resistance ,Drug Resistance, Bacterial ,medicine ,Escherichia coli ,Humans ,030212 general & internal medicine ,Cephalosporin Resistance ,Retrospective Studies ,2. Zero hunger ,0303 health sciences ,Multidisciplinary ,biology ,Bacteria ,030306 microbiology ,Pseudomonas aeruginosa ,Antimicrobials ,Models, Theoretical ,biology.organism_classification ,3. Good health ,Anti-Bacterial Agents ,Ceftriaxone ,Medicine ,France ,Enterobacter cloacae ,medicine.drug - Abstract
IntroductionThe burden of antibiotic resistance is currently estimated by mathematical modeling, without real count of resistance to key antibiotics. Here we report the real rate of resistance to key antibiotics in bacteria isolated from humans during a 5 years period in a large area in southeast in France.MethodsWe conducted a retrospective study on antibiotic susceptibility of 539,107 clinical strains isolated from hospital and private laboratories in south of France area from January 2014 to January 2019. The resistance rate to key antibiotics as well as the proportion of bacteria classified as Difficult-to-Treat (DTR) were determined and compared with the Mann-Whitney U test, the χ2 test or the Fisher’s exact test.ResultsAmong 539,037 isolates, we did not observe any significant increase or decrease in resistance to key antibiotics for 5 years, (oxacillin resistance inStaphylococcus aureus, carbapenem resistance in enterobacteria andPseudomonas aeruginosaand 3rdgeneration cephalosporin resistance inEscherichia coliandKlebsiella pneumoniae). However, we observed a significant decrease in imipenem resistance forAcinetobacter baumanniifrom 2014 to 2018 (24.19% to 12.27%; p=0.005) and a significant increase of ceftriaxone resistance inKlebsiella pneumoniae(9.9% to 24,03%; p=0.001) andEnterobacter cloacae(24,05% to 42,05%; p=0.004). Of these 539,037 isolates, 1,604 (0.3%) had a DTR phenotype.ConclusionOver a 5-year period, we did not observe a burden of AR in our region despite a high rate of antibiotic consumption in our country. These results highlight the need for implementation of real-time AR surveillance systems which use factual data.
- Published
- 2020
- Full Text
- View/download PDF
28. Shallow sequencing: a cost-effective and accurate alternative to WGS for taxonomic profiling ?
- Author
-
Goutorbe, Benoit, Abraham, Anne-Laure, Mariadassou, Mahendra, Loux, Valentin, Rué, Olivier, Plauzolles, Anne, Bidaut, Ghislain, Halfon, Philippe, Schbath, Sophie, Mathématiques et Informatique Appliquées du Génome à l'Environnement [Jouy-En-Josas] (MaIAGE), Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), ALPHABIO - Laboratoire de biologie médicale, Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Aix Marseille Université (AMU), Université Paris-Saclay, INRAE, BioinfOmics, MIGALE bioinformatics facility (MIGALE), Université Paris-Saclay-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), and Abraham, Anne-Laure
- Subjects
[SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitology ,[INFO.INFO-BI]Computer Science [cs]/Bioinformatics [q-bio.QM] ,[SDV.MP] Life Sciences [q-bio]/Microbiology and Parasitology ,ComputingMilieux_MISCELLANEOUS ,[INFO.INFO-BI] Computer Science [cs]/Bioinformatics [q-bio.QM] - Abstract
International audience
- Published
- 2020
29. Different sensitivity of CD19-positive bone marrow and lymph node lymphoblasts may cause resistance to blinatumomab in relapsed B-cell acute lymphoblastic leukemia/lymphoma
- Author
-
Geoffroy Venton, Raphaelle Fanciullino, Cédric Mercier, J Colle, Régis T. Costello, Vadim Ivanov, Cécile Colavolpe, Corinne Nicolino-Brunet, Isabelle Arnoux, Yael Berda-Haddad, Hubert Lepidi, Gleb E. Ivanov, Laure Farnault, Simulation and Modeling of Adaptive Response for Therapeutics in Cancer (SMARTc), Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Méthodes computationnelles pour la prise en charge thérapeutique en oncologie : Optimisation des stratégies par modélisation mécaniste et statistique (COMPO), Inria Sophia Antipolis - Méditerranée (CRISAM), Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria)-Centre de Recherche en Cancérologie de Marseille (CRCM), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Aix Marseille Université (AMU), Assistance Publique - Hôpitaux de Marseille (APHM), Hôpital de la Conception [CHU - APHM] (LA CONCEPTION), Laboratoire d'hématologie biologique [Hôpital de la Timone - Hôpital Nord - APHM], Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Service d'Anatomie Pathologique et de Neuropathologie, Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Theories and Approaches of Genomic Complexity (TAGC), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Microbes évolution phylogénie et infections (MEPHI), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Hôpital de la Timone [CHU - APHM] (TIMONE), and Laboratoire de Biologie médicale, AP-HM
- Subjects
Cancer Research ,Lymphoma ,[SDV]Life Sciences [q-bio] ,Antigens, CD19 ,Antineoplastic Agents ,CD19 ,03 medical and health sciences ,0302 clinical medicine ,Antigen ,[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system ,Bone Marrow ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,Precursor B-Cell Lymphoblastic Leukemia-Lymphoma ,hemic and lymphatic diseases ,Antibodies, Bispecific ,medicine ,Humans ,[SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology ,Lymph node ,ComputingMilieux_MISCELLANEOUS ,B-Lymphocytes ,[SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases ,biology ,business.industry ,Lymphoblast ,hemic and immune systems ,Hematology ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,medicine.disease ,[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology ,3. Good health ,medicine.anatomical_structure ,Oncology ,030220 oncology & carcinogenesis ,[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology ,biology.protein ,Cancer research ,Blinatumomab ,Lymph Nodes ,Bone marrow ,Antibody ,business ,030215 immunology ,medicine.drug - Abstract
Blinatumomab, a new bispecific CD19/CD3 T-cell engager antibody, has been shown to improve the outcome in patients with relapsed and/or refractory B-cell acute lymphoblastic leukemia (R/R ALL) comp...
- Published
- 2020
- Full Text
- View/download PDF
30. Association of Autofluorescence-Based Detection of the Parathyroid Glands During Total Thyroidectomy With Postoperative Hypocalcemia Risk : Results of the PARAFLUO Multicenter Randomized Clinical Trial
- Author
-
Nicolas Turrin, Fares Benmiloud, Laurent Chiche, Régis Gras, Nathalie Chereau, Gaelle Godiris-Petit, Séverine Noullet, Jean-Charles Gillot, Stanislas Rebaudet, Guillaume Penaranda, Jean Gaudart, Hôpital Européen [Fondation Ambroise Paré - Marseille], CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Saint-Joseph [Marseille], ALPHABIO - Laboratoire de biologie médicale, Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Biostatistique et technologies de l'information et de la communication (BioSTIC) - [Hôpital de la Timone - APHM] (BiosTIC ), Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Dupuis, Christine, and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)
- Subjects
Male ,Organs at Risk ,medicine.medical_treatment ,[SDV]Life Sciences [q-bio] ,Surgical Wound ,030230 surgery ,law.invention ,Intraoperative Period ,0302 clinical medicine ,Postoperative Complications ,Randomized controlled trial ,law ,MESH: Postoperative Complications ,Single-Blind Method ,Prospective Studies ,Prospective cohort study ,MESH: Middle Aged ,MESH: Organs at Risk ,Confounding ,Optical Imaging ,Middle Aged ,MESH: Transplantation, Autologous ,3. Good health ,[SDV] Life Sciences [q-bio] ,MESH: Parathyroid Glands ,030220 oncology & carcinogenesis ,Thyroidectomy ,Female ,MESH: Hypocalcemia ,medicine.medical_specialty ,Randomization ,Transplantation, Autologous ,Fluorescence ,MESH: Thyroidectomy ,Parathyroid Glands ,03 medical and health sciences ,medicine ,Humans ,MESH: Intraoperative Period ,MESH: Optical Imaging ,MESH: Humans ,Hypocalcemia ,business.industry ,MESH: Surgical Wound ,MESH: Fluorescence ,Odds ratio ,MESH: Single-Blind Method ,MESH: Prospective Studies ,MESH: Male ,Surgery ,Transplantation ,business ,MESH: Female - Abstract
International audience; Importance: Because inadvertent damage of parathyroid glands can lead to postoperative hypocalcemia, their identification and preservation, which can be challenging, are pivotal during total thyroidectomy.Objective: To determine if intraoperative imaging systems using near-infrared autofluorescence (NIRAF) light to identify parathyroid glands could improve parathyroid preservation and reduce postoperative hypocalcemia.Design, setting, and participants: This randomized clinical trial was conducted from September 2016 to October 2018, with a 6-month follow-up at 3 referral hospitals in France. Adult patients who met eligibility criteria and underwent total thyroidectomy were randomized. The exclusion criteria were preexisting parathyroid diseases.Interventions: Use of intraoperative NIRAF imaging system during total thyroidectomy.Main outcomes and measures: The primary outcome was the rate of postoperative hypocalcemia (a corrected calcium
- Published
- 2020
- Full Text
- View/download PDF
31. Baseline and Post-Treatment Hepatitis C NS5A Resistance in Relapsed Patients from a Multicentric Real-Life Cohort
- Author
-
Philippe Halfon, Jacques Izopet, Pascale Trimoulet, Caroline Scholtes, Sofiane Mohamed, Denis Ouzan, Laurent Chiche, Victor de Ledinghen, Hacène Khiri, Marc Bourlière, M.A. Thelu, Sophie Metivier, Guillaume Penaranda, Anne Plauzolles, Laurent Alric, Vincent Leroy, Fabien Zoulim, Sylvie Larrat, Florence Abravanel, ALPHABIO - Laboratoire de biologie médicale, Centre de Recherche en Cancérologie de Lyon (CRCL), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse], Institut de biologie structurale (IBS - UMR 5075), Institut de Recherche Interdisciplinaire de Grenoble (IRIG), Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Grenoble Alpes (UGA)-Centre National de la Recherche Scientifique (CNRS), Service de virologie et d'immunologie biologique, CHU Bordeaux [Bordeaux]-Groupe hospitalier Pellegrin, Service d'Hépatologie et de Gastroentérologie [Lyon], Hospices Civils de Lyon (HCL), Institut de Recherche en Santé Digestive (IRSD ), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Recherche Agronomique (INRA)-Ecole Nationale Vétérinaire de Toulouse (ENVT), Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Gastro-entérologie - Hépatologie [Purpan], CHU Toulouse [Toulouse]-Hôpital Purpan [Toulouse], Hôpital Michallon, Institut Arnault Tzanck, Service d'Hépato-Gastro-Entérologie, CHU Bordeaux [Bordeaux]-Hôpital Saint-André, Institut d'oncologie/développement Albert Bonniot de Grenoble (INSERM U823), Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-EFS-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de médecine interne [Hôpital Nord - APHM], Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital Nord [CHU - APHM], Service d'hépatologie et de gastroentérologie [Hôpital Saint-Joseph - Marseille], Aix Marseille Université (AMU)-Hôpital Saint-Joseph [Marseille], Centre de Physiopathologie Toulouse Purpan ex IFR 30 et IFR 150 (CPTP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS), Hôpital Européen [Fondation Ambroise Paré - Marseille], Centre Hospitalier Universitaire de Lyon (CHU Lyon), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Centre Hospitalier Universitaire [Grenoble] (CHU), CHU Bordeaux [Bordeaux], Pharmacochimie et Biologie pour le Développement (PHARMA-DEV), Institut de Recherche pour le Développement (IRD)-Institut de Chimie de Toulouse (ICT), Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université de Toulouse (UT)-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT), Hôpital Haut-Lévêque [CHU Bordeaux], Hôpital Saint-Joseph [Marseille], Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie de Toulouse (ICT-FR 2599), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie du CNRS (INC)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Institut de Chimie du CNRS (INC)-Institut de Recherche pour le Développement (IRD), Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon], Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut de biologie structurale (IBS - UMR 5075 ), Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut de Recherche Interdisciplinaire de Grenoble (IRIG), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Institut de Recherche pour le Développement (IRD)-Institut de Chimie de Toulouse (ICT-FR 2599), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées, Physiopathologie du cancer du foie, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut National de la Santé et de la Recherche Médicale (INSERM)-EFS-CHU Grenoble-Université Joseph Fourier - Grenoble 1 (UJF), Laboratoire de Virologie [CHU Purpan, Toulouse], Institut Fédératif de Biologie (IFB) - Hôpital Purpan, CHU Toulouse [Toulouse]-CHU Toulouse [Toulouse]-Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse]-CHU Toulouse [Toulouse], Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut National de la Recherche Agronomique (INRA)-Université Toulouse III - Paul Sabatier (UT3), and Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Ecole Nationale Vétérinaire de Toulouse (ENVT)
- Subjects
Male ,0301 basic medicine ,DNA Mutational Analysis ,Viral Nonstructural Proteins / genetics ,Drug Resistance ,Hepacivirus ,Drug resistance ,Viral Nonstructural Proteins ,Virological response ,Viral Nonstructural Proteins / antagonists & inhibitors ,0302 clinical medicine ,Medicine ,Pharmacology (medical) ,Viral ,Treatment Failure ,Hepatitis C ,Viral Load ,[SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciences ,3. Good health ,[SDV.BBM.BS]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Biomolecules [q-bio.BM] ,Treatment Outcome ,Infectious Diseases ,Antiviral Agents / pharmacology ,Cohort ,Drug Therapy, Combination ,Female ,030211 gastroenterology & hepatology ,Viral load ,Hepacivirus / genetics ,medicine.medical_specialty ,Genotype ,Antiviral Agents / therapeutic use ,Antiviral Agents ,03 medical and health sciences ,Pharmacotherapy ,Drug Therapy ,Internal medicine ,Drug Resistance, Viral ,Humans ,NS5A ,Pharmacology ,business.industry ,medicine.disease ,030104 developmental biology ,Hepatitis C / virology ,Hepacivirus / drug effects ,Post treatment ,Hepatitis C / drug therapy ,business - Abstract
Background Recent data have suggested that failure to achieve sustained virological response with direct-acting antiviral therapy is usually due to relapse and is primarily associated with the emergence of resistance-associated substitutions. The aim of this study was to investigate the prevalence and characterization of non-structural-5A resistance-associated substitutions in patients infected with HCV genotypes 1, 3 and 4 treated by direct-acting antiviral therapy, including anti-non-structural-5A, and to characterize the pre-existing resistance-associated substitutions in subjects treated with anti-non-structural-5A inhibitors. Methods From January 2014 to March 2016, 2,995 patients infected with HCV genotypes 1, 3 and 4 were exposed to non-structural-5A inhibitors. Sequencing results at the time of virological failure were available for 61 patients; sequencing at baseline was available for 35 of these patients. Results Among the 35 patients with sequencing results available at baseline, 15 had no resistance-associated substitution, 16 had only one resistance-associated substitution, and 4 had more than one resistance-associated substitution. Resistance-associated substitutions were harbored in 57% of the sequences in the non-structural-5A region. Among the 61 patients sequenced at virological failure, 50 (82%) patients presented at least one resistance-associated substitutions inducing a high level of resistance to non-structural-5A inhibitors (>10-fold resistance). Conclusions This pooled analysis suggests that non-structural-5A resistance-associated substitutions screening should be recommended when considering retreatment with a non-structural-5A inhibitor regimen in patients who have previously experienced failed non-structural-5A treatment.
- Published
- 2017
- Full Text
- View/download PDF
32. The zoonotic pathogen Leptospira interrogans mitigates environmental stress through cyclic-di-GMP-controlled biofilm production
- Author
-
Julien Fernandes, Emilie Bierque, Dominique Girault, Malia Kainiu, Mathieu Picardeau, Joëlle Vinh, Nicolas Eskenazi, Anthony Douyère, Heike Bähre, Marie-Estelle Soupé-Gilbert, Roman Thibeaux, Cyrille Goarant, Unité de Recherche et d'Expertise Leptospirose - Leptospirosis Research and Expertise Unit [Nouméa, Nouvelle-Calédonie] (UREL), Institut Pasteur de Nouvelle-Calédonie, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP), BioImagerie Photonique – Photonic BioImaging (UTechS PBI), Institut Pasteur [Paris] (IP), Hannover Medical School [Hannover] (MHH), Institut de sciences exactes et appliquées (ISEA), Université de la Nouvelle-Calédonie (UNC), Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI Paris), Université Paris sciences et lettres (PSL), Spectrométrie de Masse Biologique et Protéomique (USR3149 / FRE2032) (SMBP), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS), Centre Collaborateur FAO/OMS pour l'épidémiologie de la leptospirose, Centre National de Référence de la Leptospirose - National Reference Center Leptospirosis (CNR), Biologie des Spirochètes / Biology of Spirochetes, This work was funded by a postdoctoral fellowship awarded by the AXA Research Fund (reference: 15-AXA-PDOC-037). Lastly, we thank the UTechS Photonic BioImaging facility (Imagopole, C2RT, Institut Pasteur) funded by the French National Research Agency (France BioImaging, ANR-10–INSB–04, Investments for the Future programme)., The authors thank Johann Peltier, Nadia Benaroudj, Robert Antony Gaultney, Linda Guentas, Arnaud Tarantola and Catherine Inizan for technical assistance and critical discussions. The authors are indebted to Professor Jean-Marc Ghigo for critical discussions and support at the start of this project. We thank Julien Colot and the Laboratoire de Biologie Médicale at Centre Hospitalier Territorial Gaston Bourret for granting access to their MALDI-TOF facilities. We also thank the CRESICA consortium for granting access to the electron microscopy facilities., ANR-10-INBS-0004,France-BioImaging,Développment d'une infrastructure française distribuée coordonnée(2010), and Institut Pasteur [Paris]
- Subjects
Cyclic di-GMP ,Bacterial Zoonoses ,Virulence ,Applied Microbiology and Biotechnology ,Microbiology ,lcsh:Microbial ecology ,Article ,03 medical and health sciences ,chemistry.chemical_compound ,Spatio-Temporal Analysis ,Bacterial Proteins ,Stress, Physiological ,Guanosine monophosphate ,Animals ,Humans ,Cyclic GMP ,030304 developmental biology ,0303 health sciences ,biology ,Environmental microbiology ,030306 microbiology ,Phosphoric Diester Hydrolases ,Escherichia coli Proteins ,Biofilm ,Biofilm matrix ,Gene Expression Regulation, Bacterial ,biochemical phenomena, metabolism, and nutrition ,biology.organism_classification ,[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology ,3. Good health ,chemistry ,Biofilms ,Mutation ,biology.protein ,lcsh:QR100-130 ,Diguanylate cyclase ,Leptospira interrogans ,Phosphorus-Oxygen Lyases ,Bacteria ,Biotechnology - Abstract
The zoonotic bacterium Leptospira interrogans is the aetiological agent of leptospirosis, a re-emerging infectious disease that is a growing public health concern. Most human cases of leptospirosis result from environmental infection. Biofilm formation and its contribution to the persistence of virulent leptospires in the environment or in the host have scarcely been addressed. Here, we examined spatial and time-domain changes in biofilm production by L. interrogans. Our observations showed that biofilm formation in L. interrogans is a highly dynamic process and leads to a polarized architecture. We notably found that the biofilm matrix is composed of extracellular DNA, which enhances the biofilm’s cohesiveness. By studying L. interrogans mutants with defective diguanylate cyclase and phosphodiesterase genes, we show that biofilm production is regulated by intracellular levels of bis-(3′–5′)-cyclic dimeric guanosine monophosphate (c-di-GMP) and underpins the bacterium’s ability to withstand a wide variety of simulated environmental stresses. Our present results show how the c-di-GMP pathway regulates biofilm formation by L. interrogans, provide insights into the environmental persistence of L. interrogans and, more generally, highlight leptospirosis as an environment-borne threat to human health.
- Published
- 2020
- Full Text
- View/download PDF
33. Angiostrongylus cantonensis Infection of Central Nervous System, Guiana Shield
- Author
-
Emma Cuadro-Alvarez, Elise Martin, Loïc Epelboin, Antoine Defo, Céline Dard, Annabelle Brunelin, Dorothée Harrois, Yvonne Qvarnstrom, Narcisse Elenga, Falucar Njuieyon, Magalie Demar, Yajaira Mrsic, Fanny Henaff, Denis Blanchet, Nicole Desbois-Nogard, Noémie Lachaume, Chimène Maniassom, Service de Pédiatrie [Cayenne, Guyanne Française], Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française], Groupe d'histoire et diffusion des sciences d'Orsay (GHDSO), Université Paris-Sud - Paris 11 (UP11), Unité des Maladies Infectieuses et Tropicales (UMIT), Université de Guyane (UG), Laboratoire de Biologie Médicale [CH Basse-Terre, Guadeloupe], Centre Hospitalier de Basse-Terre [Guadeloupe], Laboratoire de Microbiologie, CHU Pointe-à-Pitre/Abymes [Guadeloupe], Department of parasitic diseases, Centers for Disease Control, Medicine Department, Ecosystemes Amazoniens et Pathologie Tropicale (EPat), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Guyane (UG)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Guyane (UG), Laboratoire de parasitologie-mycologie, CHU Grenoble, EA 3593 Université des Antilles et de la Guyane, Service de Pédiatrie, and Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française]-Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française]
- Subjects
Microbiology (medical) ,Pathology ,medicine.medical_specialty ,Eosinophilic Meningitis ,Epidemiology ,Central nervous system ,030231 tropical medicine ,lcsh:Medicine ,parasites ,Angiostrongylus cantonensis infection ,Transverse myelitis ,Serology ,lcsh:Infectious and parasitic diseases ,03 medical and health sciences ,Cerebrospinal fluid ,0302 clinical medicine ,transverse myelitis ,eosinophilic meningitis ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,parasitic diseases ,medicine ,lcsh:RC109-216 ,030212 general & internal medicine ,[SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases ,biology ,business.industry ,lcsh:R ,Angiostrongylus cantonensis ,medicine.disease ,biology.organism_classification ,3. Good health ,medicine.anatomical_structure ,Infectious Diseases ,Guiana Shield ,nematodes ,Angiostrongyliasis ,meningitis/encephalitis ,business - Abstract
International audience; We report a case of eosinophilic meningitis complicated by transverse myelitis caused by Angiostrongylus cantonensis in a 10-year-old boy from Brazil who had traveled to Suriname. We confirmed diagnosis by serology and real-time PCR in the cerebrospinal fluid. The medical community should be aware of angiostrongyliasis in the Guiana Shield.
- Published
- 2018
- Full Text
- View/download PDF
34. PREDOMOS study, impact of a social intervention program for socially isolated elderly cancer patients: update to the study protocol for a randomized controlled trial
- Author
-
Anne-Laure Couderc, Emilie Nouguerède, Karine Baumstarck, Sandrine Loubière, Hervé Le Caer, Olivier Guillem, Frédérique Rousseau, Laurent Greillier, Emmanuelle Norguet-Monnereau, Maud Cecile, Rabia Boulahssass, Françoise Le Caer, Sandrine Tournier, Chantal Butaud, Pierre Guillet, Sophie Nahon, Sylvie Kirscher, Nadine Diaz, Claire Morando, Patrick Villani, Pascal Auquier, Aurélie Daumas, Centre de Recherches en Oncologie biologique et Oncopharmacologie (CRO2), Aix Marseille Université (AMU)- Hôpital de la Timone [CHU - APHM] (TIMONE)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre d'études et de recherche sur les services de santé et la qualité de vie (CEReSS), Aix Marseille Université (AMU), Respiratory Pathology Department, Centre Hospitalier de la Dracénie [Draguignan], Service d'Oncologie Médicale, Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service d'oncologie multidisciplinaire innovations thérapeutiques [Hôpital Nord - APHM], Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital Nord [CHU - APHM], Laboratoire de Biologie médicale, AP-HM, Assistance Publique - Hôpitaux de Marseille (APHM), Santé Publique et maladies Chroniques : Qualité de vie Concepts, Usages et Limites, Déterminants (SPMC), Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM), Hôpital de la Timone [CHU - APHM] (TIMONE), Laboratoire de Santé Publique, Université de la Méditerranée - Aix-Marseille 2, Vecteurs - Infections tropicales et méditerranéennes (VITROME), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées (IRBA), Anthropologie bio-culturelle, Droit, Ethique et Santé (ADES), and Aix Marseille Université (AMU)-EFS ALPES MEDITERRANEE-Centre National de la Recherche Scientifique (CNRS)
- Subjects
Older patient, cancer ,[SDV]Life Sciences [q-bio] ,Medicine (miscellaneous) ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Update ,Cost effectiveness ,[SHS]Humanities and Social Sciences ,03 medical and health sciences ,Older patient ,0302 clinical medicine ,[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,cancer ,Pharmacology (medical) ,[SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology ,030212 general & internal medicine ,ComputingMilieux_MISCELLANEOUS ,Social intervention program ,lcsh:R5-920 ,[SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases ,030503 health policy & services ,Oncogeriatrics ,[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology ,3. Good health ,Randomized controlled trial ,[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology ,Techniques of domotic and remote assistance ,lcsh:Medicine (General) ,0305 other medical science ,[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology - Abstract
Background Social isolation potentiates the risk of death by cancer in the older cancer patient population. The PREDOMOS study investigates the impact of establishing a Program of Social intervention associated with techniques of Domotic and Remote assistance on the improvement of quality of life of older isolated patients, treated for locally advanced or metastatic cancer. This paper updates the pilot trial protocol. Methods/design The original protocol was published in Trials, accessible at https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-017-1894-7. This update reports on the eligibility criteria expansion and on the adjunction of a cost-utility analysis. We widened the eligible population to patients with locally advanced or metastatic cancer including malignant hemopathies (except acute myeloid leukemia) and to patients in the first and second lines of oncologic treatment. We restricted the inclusion to patients with a Mini Mental State Examination score strictly over 24. In addition to the secondary outcomes outlined in the protocol, a medico-economic analysis has been added to evaluate both the health benefits and costs of the two strategies and calculate the incremental cost-utility ratio of the innovative program assessed, compared to the standard practice. Trial registration ClinicalTrials.gov, NCT02829762. Registered on 29 June 2016.
- Published
- 2019
- Full Text
- View/download PDF
35. PROFIL DES UTILISATEURS DU PREMIER KIT DE DÉPISTAGE PAR AUTOPRÉLÈVEMENT DU PROGRAMME MÉMODÉPISTAGES PROPOSÉ AUX HSH MULTIPARTENAIRES EN FRANCE EN 2018
- Author
-
Rahib, Delphine, Delagreverie, Héloïse, Gabassi, Audrey, Touré, Tassiry, Thi, Than-Thuy Le, Vassel, Eléonore, Vodosin, Pierre, Leveau, Benjamin, Coz, Lucas Le, Pisoni, Amandine, Delaugerre, Constance, Icard, Vinca, Digne, Julien, Tuaillon, Edouard, Lydié, Nathalie, Santé publique France - French National Public Health Agency [Saint-Maurice, France], Laboratoire de Virologie [CHU Saint-Louis], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hospices Civils de Lyon (HCL), ALPHABIO - Laboratoire de biologie médicale, Pathogénèse et contrôle des infections chroniques (PCCI), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Montpellier (CHU Montpellier )-Université de Montpellier (UM)
- Subjects
HSH ,Dépistage ,IST ,Screening ,Self-sampling ,MSM ,STI ,[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology ,Autoprélèvement - Abstract
International audience; In 2017, the French National Authority for Health’s guidelines for HIV screening stated that men who havesex with men (MSM) should be screened every three months. This pace was defined to reduce the intervalbetween infection and diagnosis and the proportion of undiagnosed people for HIV. To support the implementationof these guidelines, a wide range of screening options were available – laboratory, anonymousscreening centers, self-administered tests, community screening– but there were fewer options for othersexually transmitted infections (STIs). To help MSM repeat the HIV screening while taking into considerationthe STIs issue, Santé publique France developed the MemoDepistages program designed for multi-partnerMSM. Advertised online in spring 2018, the program offered MSM with multiple partners a self-samplingkit (SSK) for HIV, HBV, HCV, syphilis, and gonococcal and chlamydia infections. Among the 7,158 men whowere offered the kit, 27.2% used it to make at least one of the four tests proposed. Users lived mainly in bigcities, were highly educated and frequent users of gay meeting venues. Sociodemographic factors (age,diploma) were strongly associated with using the kit. SSK was used by 30% of our sample with small variationbetween the different groups, and addressed a diverse population regarding socio-demographic and HIVscreening habits at baseline.; En 2017, la Haute Autorité de Santé (HAS) a fixé à trois mois la fréquence optimale de dépistage pour le VIHdes hommes ayant des relations sexuelles avec d’autres hommes (HSH) afin de réduire le délai entre la datede l’infection et le diagnostic et la part des personnes vivant avec le VIH non diagnostiquées. Ces objectifss’appuientsur une offre variée de dépistage du VIH – laboratoires, centres de dépistages anonymes, autotests,dépistages communautaires – mais moins diversifiée pour les autres infections sexuellement transmissibles (IST).Afin d’encouragerle dépistage répété du VIH tout en tenant compte des enjeux relatifs au dépistage des autresIST, Santé publique France a construit le programme MémoDépistages à destination de HSH multipartenaires.Promu en ligne au printemps 2018, ce programme proposait un kit d’autoprélèvement pour réaliser le dépistagedu VIH, du VHB, du VHC, de la syphilis, des infections à chlamydia et à gonocoques. Parmi les 7 158 hommeséligibles auxquels un kit d’autoprélèvement a été proposé, 27,2% l’ont utilisé pour réaliser au moins l’un desquatre prélèvements proposés. Il s’agissait majoritairement d’hommes citadins, avec un haut niveau d’étude,familiers des lieux de convivialité gay. Ce sont principalement les facteurs sociodémographiques (âge, niveaud’étude) qui étaient associés à un taux élevé d’utilisation de l’autoprélèvement dans l’étude. Utilisé par près de30% des hommes auxquels il est proposé, le kit d’autoprélèvement permet d’amener au dépistage une populationdiversifiée tant en termes sociodémographiques qu’en termes de comportements face au dépistage.
- Published
- 2019
36. A proactive approach to assess rising STIs among different at-risk groups of MSM in the early era of PrEP: a real-world clinical care setting
- Author
-
Psomas, CK, Halfon, Philippe, Pénaranda, Guillaume, Retornaz, F., Khiri, H., Delord, M., Rebaudet, Stanislas, Chiche, Laurent, Philibert, Patrick, ALPHABIO - Laboratoire de biologie médicale, Microbes évolution phylogénie et infections (MEPHI), Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU), Laboratoire Alphabio, Laboratoire alphabio, Hôpital Européen [Fondation Ambroise Paré - Marseille], Aix Marseille Université (AMU), and Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS)
- Subjects
[SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases ,[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology ,[SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology ,[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology ,ComputingMilieux_MISCELLANEOUS - Abstract
International audience
- Published
- 2019
37. Meeting Abstract: 745P
- Author
-
Awada, A, Harding, J, Kotecki, Nuria, Aftimos, P, Decaens, T., Dreyer, C., Ansaldi, Christelle, Rachid, M, Serdjebi, C., Halfon, Philippe, Abou-Alfa, G, Raymond, E, Microbes évolution phylogénie et infections (MEPHI), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), and ALPHABIO - Laboratoire de biologie médicale
- Subjects
[SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases ,[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology ,[SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology ,[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology ,ComputingMilieux_MISCELLANEOUS - Abstract
International audience
- Published
- 2019
38. Lethal toxicities after capecitabine intake in a previously 5-FU-treated patient: why dose matters with dihydropryimidine dehydrogenase deficiency
- Author
-
L'Houcine Ouafik, Crescent C Gbeto, Catherine Roche, Bruno Lacarelle, Sylvie Quaranta, Thierry Allegre, Sophie Nahon, Roxane Mari, Raphaelle Fanciullino, Caroline Solas, Joseph Ciccolini, Centre Hospitalier d'Aix en Provence [Aix-en-Provence] (CHIAP ), Laboratoire de Biologie médicale, AP-HM, Assistance Publique - Hôpitaux de Marseille (APHM), Simulation and Modeling of Adaptive Response for Therapeutics in Cancer (SMARTc), Centre de Recherche en Cancérologie de Marseille (CRCM), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Aix Marseille Université (AMU), Laboratoire de Transfert d'Oncologie Biologique [Hôpital Nord - APHM], Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital Nord [CHU - APHM], Institut de neurophysiopathologie (INP), Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Pharmacocinétique Toxicocinétique - [Hôpital de la Timone - APHM], Hôpital de la Timone [CHU - APHM] (TIMONE)-Assistance Publique - Hôpitaux de Marseille (APHM), Service Hématologie et Médecine Interne, Centre Hospitalier du Pays d'Aix, Centre National de la Recherche Scientifique (CNRS)-Aix Marseille Université (AMU), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), and Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE)
- Subjects
medicine.medical_specialty ,Antimetabolites, Antineoplastic ,Dihydropyrimidine Dehydrogenase Deficiency ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Breast Neoplasms ,Vinorelbine ,Gastroenterology ,Capecitabine ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Internal medicine ,Genetics ,Medicine ,Humans ,Dosing ,ComputingMilieux_MISCELLANEOUS ,Dihydrouracil Dehydrogenase (NADP) ,030304 developmental biology ,Pharmacology ,0303 health sciences ,business.industry ,Dihydrouracil ,Middle Aged ,medicine.disease ,Metastatic breast cancer ,3. Good health ,chemistry ,030220 oncology & carcinogenesis ,Toxicity ,Molecular Medicine ,DPYD ,Female ,Fluorouracil ,business ,Pharmacogenetics ,medicine.drug - Abstract
Dihydropryimidine dehydrogenase (DPD) deficiency is a pharmacogenetic syndrome associated with severe or lethal toxicities with oral capecitabine. Usually, patients with history of 5-FU-based therapy with no signs for life-threatening toxicities are considered as not DPD-deficient individuals who can be safely treated next with capecitabine if required. Here we describe the case of a woman originally treated with standard FEC100 protocol for metastatic breast cancer with little severe toxicities but grade-3 mucosities that were quickly resolved by symptomatic treatment. When switched to capecitabine + vinorelbine combo, extremely severe toxicities with fatal outcome were unexpectedly observed. Pharmacogenetic investigations were performed on cytidine deaminase and DPYD, and showed that this patient was heterozygous for the 2846A>T mutation on the DPYD gene. DPD phenotyping (i.e., uracil plasma levels >250 ng/ml, dihydrouracil/uracil ratio 2 5-FU) and capecitabine (i.e., 2250 mg daily) could explain why initial 5-FU-based protocol did not lead to life-threatening toxicities, whereas capecitabine rapidly triggered toxic death. Overall, this case report suggests that any toxicity, even when not life threatening, should be considered as a warning signal for possible underlying profound DPD deficiency syndrome, especially with low-dose protocols.
- Published
- 2019
- Full Text
- View/download PDF
39. Simultaneous determination of cytosine arabinoside and its metabolite uracil arabinoside in human plasma by LC-MS/MS: Application to pharmacokinetics-pharmacogenetics pilot study in AML patients
- Author
-
Bruno Lacarelle, Régis Costello, Le Thi Thu Hau, Mélanie Donnette, Caroline Solas, Madeleine Giocanti, Raphaelle Fanciullino, Geoffroy Venton, L'Houcine Ouafik, Laure Farnault, Joseph Ciccolini, Yael Berda-Haddad, Simulation and Modeling of Adaptive Response for Therapeutics in Cancer (SMARTc), Centre de Recherche en Cancérologie de Marseille (CRCM), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Aix Marseille Université (AMU), Laboratoire de pharmacocinétique et toxicologie [Hôpital de la Timone - APHM], Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Service d’hématologie et de thérapie cellulaire, Hôpital de la Conception [CHU - APHM] (LA CONCEPTION), Laboratoire de Biologie médicale, AP-HM, Assistance Publique - Hôpitaux de Marseille (APHM), Service de Transfert d’Oncologie Biologique, Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital Nord [CHU - APHM], Institut de neurophysiopathologie (INP), Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Pharmacocinétique Toxicocinétique - [Hôpital de la Timone - APHM], Hôpital de la Timone [CHU - APHM] (TIMONE)-Assistance Publique - Hôpitaux de Marseille (APHM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre National de la Recherche Scientifique (CNRS)-Aix Marseille Université (AMU), Méthodes computationnelles pour la prise en charge thérapeutique en oncologie : Optimisation des stratégies par modélisation mécaniste et statistique (COMPO), Inria Sophia Antipolis - Méditerranée (CRISAM), and Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria)-Centre de Recherche en Cancérologie de Marseille (CRCM)
- Subjects
Metabolite ,[SDV]Life Sciences [q-bio] ,Clinical Biochemistry ,Pilot Projects ,MESH: Arabinofuranosyluracil ,Pharmacology ,030226 pharmacology & pharmacy ,01 natural sciences ,Biochemistry ,Analytical Chemistry ,MESH: Linear Models ,chemistry.chemical_compound ,0302 clinical medicine ,Tandem Mass Spectrometry ,MESH: Drug Monitoring ,MESH: Cytarabine ,ComputingMilieux_MISCELLANEOUS ,Chromatography, High Pressure Liquid ,media_common ,MESH: Antimetabolites, Antineoplastic ,Chemistry ,Cytarabine ,Myeloid leukemia ,General Medicine ,Cytidine deaminase ,3. Good health ,MESH: Reproducibility of Results ,Leukemia, Myeloid, Acute ,Drug Monitoring ,MESH: Leukemia, Myeloid, Acute ,medicine.drug ,Drug ,Antimetabolites, Antineoplastic ,media_common.quotation_subject ,Purine analogue ,Acute myeloid leukemia patients ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Sensitivity and Specificity ,03 medical and health sciences ,Pharmacokinetics ,medicine ,Humans ,LC-MS/MS ,MESH: Chromatography, High Pressure Liquid ,Chromatography ,MESH: Humans ,010401 analytical chemistry ,Arabinofuranosyluracil ,Reproducibility of Results ,MESH: Tandem Mass Spectrometry ,Cell Biology ,MESH: Pilot Projects ,MESH: Sensitivity and Specificity ,0104 chemical sciences ,Linear Models ,Pharmacogenetics - Abstract
International audience; Purine analogs like aracytine (AraC) are a mainstay for treating acute myeloid leukemia (AML). There are marked differences in drug dosing and scheduling depending on the protocols when treating AML patients with AraC. Large inter-patient pharmacokinetics variability has been reported, and genetic polymorphisms affecting cytidine deaminase (CDA), the liver enzyme responsible for the conversion of Ara-C to inactive uracil arabinoside (AraU) could be a culprit for either life-threatening toxicities or poor efficacy related to substantial changes in plasma exposure levels among patients. The quantitative determination of Ara-C in plasma is challenging due the required sensitivity because of the short half-life of this drug (i.e.
- Published
- 2019
- Full Text
- View/download PDF
40. Discordant Grading of Aortic Stenosis Severity: New Insights from an In Vitro Study
- Author
-
Viktória Stanová, Anne-Sophie Zenses, Marie-Annick Clavel, Paul Barragan, Jérôme Adda, Régis Rieu, Philippe Pibarot, Gilbert Habib, Guillaume Penaranda, Hôpital Arnaud de Villeneuve [CHRU Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Laboratoire de Biomécanique Appliquée (LBA UMR T24), Aix Marseille Université (AMU)-Université Gustave Eiffel, Quebec Heart and Lung Institute, Université Laval [Québec] (ULaval), Centre Hospitalier Privé Beauregard. (CHPB), Centre hopitalier Privé, ALPHABIO - Laboratoire de biologie médicale, Microbes évolution phylogénie et infections (MEPHI), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Quebec Heart Institute/Laval Hospital, Université Laval [Québec] (ULaval)-Quebec Heart Institute, and Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)
- Subjects
medicine.medical_specialty ,business.industry ,Effective orifice area ,030204 cardiovascular system & hematology ,medicine.disease ,03 medical and health sciences ,Stenosis ,0302 clinical medicine ,[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system ,In vitro study ,Medicine ,030212 general & internal medicine ,Low gradient ,Radiology ,Cardiology and Cardiovascular Medicine ,business ,Grading (tumors) ,ComputingMilieux_MISCELLANEOUS - Abstract
Background: Low gradient (mean gradient, < 40 mmHg) aortic stenosis (AS) may occur in conjunction with a small valve effective orifice area (EOA) < 1 cm2. This discordant grading in AS seve...
- Published
- 2019
- Full Text
- View/download PDF
41. GNS561, a new lysosomotropic small molecule, for the treatment of intrahepatic cholangiocarcinoma
- Author
-
Eric Raymond, Marie Guillemot, Sonia Brun, Philipe Halfon, Jennifer Tracz, Firas Bassissi, François Autelitano, Cindy Serdjebi, Christelle Ansaldi, Marie Novello, Philippe Fabre, Jérôme Courcambeck, Institut de Recherche en Infectiologie de Montpellier (IRIM), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Trophos S.A., Simulation & Modelling : Adaptive Response for Therapeutics in Cancer (SMARTc unit), Centre de Recherches en Oncologie biologique et Oncopharmacologie (CRO2), Aix Marseille Université (AMU)- Hôpital de la Timone [CHU - APHM] (TIMONE)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Aix Marseille Université (AMU)- Hôpital de la Timone [CHU - APHM] (TIMONE)-Institut National de la Santé et de la Recherche Médicale (INSERM), Rétrovirus et Maladies Associées, Institut National de la Santé et de la Recherche Médicale (INSERM), Microbes évolution phylogénie et infections (MEPHI), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), ALPHABIO - Laboratoire de biologie médicale, SMARTc, and Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)
- Subjects
0301 basic medicine ,Programmed cell death ,Cell Survival ,Antineoplastic Agents ,Chick Embryo ,Cholangiocarcinoma ,03 medical and health sciences ,0302 clinical medicine ,[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,Lysosome ,Cell Line, Tumor ,medicine ,Animals ,Humans ,Pharmacology (medical) ,[SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology ,Viability assay ,Intrahepatic Cholangiocarcinoma ,Pharmacology ,[SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases ,Chemistry ,[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology ,3. Good health ,Chorioallantoic membrane ,030104 developmental biology ,medicine.anatomical_structure ,Oncology ,Bile Duct Neoplasms ,Apoptosis ,Cell culture ,030220 oncology & carcinogenesis ,Cancer cell ,[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology ,Cancer research ,Lysosomes - Abstract
International audience; Among the acquired modifications in cancer cells, changes in lysosomal phenotype and functions are well described, making lysosomes a potential target for novel therapies. Some weak base lipophilic drugs have a particular affinity towards lysosomes, taking benefits from lysosomal trapping to exert anticancer activity. Here, we have developed a new lysosomotropic small molecule, GNS561, and assessed its activity in multiple in vitro intrahepatic cholangiocarcinoma models (HuCCT1 and RBE cell lines and patient-derived cells) and in a chicken chorioallantoic membrane xenograft model. GNS561 significantly reduced cell viability in two intrahepatic cholangiocarcinoma cell lines (IC 50 of 1.5 ± 0.2 μM in HuCCT1 and IC 50 of 1.7 ± 0.1 μM in RBE cells) and induced apoptosis as measured by caspases activation. We confirmed that GNS561-mediated cell death was related to its lysosomotropic properties. GNS561 induced lysosomal dysregulation as proven by inhibition of late-stage autophagy and induction of a dose-dependent build-up of enlarged lysosomes. In patient-derived cells, GNS561 was more potent than cisplatin and gemcitabine in 2/5 and 1/5 of the patient-derived cells models, respectively. Moreover, in these models, GNS561 was potent in models with low sensitivity to gemcitabine. GNS561 was also efficient in vivo against a human intrahepatic cholangiocarcinoma cell line in a chicken chorioallantoic membrane xenograft model, with a good tolerance at doses high enough to induce an antitumor effect in this model. In summary, GNS561 is a new lysosomotropic agent, with an anticancer activity against intrahepatic cholan-giocarcinoma. Further investigations are currently ongoing to fully elucidate its mechanism of action.
- Published
- 2019
- Full Text
- View/download PDF
42. Prevalence and risk factors of sexually transmitted infections among French service members
- Author
-
Henri Panjo, Jean Baptiste Meynard, S. Duron, Aline Bohet, Caroline Moreau, Audrey Mérens, Nathalie Bajos, C. Bigaillon, Sébastien Sicard, Centre Militaire Français d'Epidémiologie et de Santé Publique [Marseille], Centre d'épidémiologie et de santé publique des armées [Marseille] (CESPA), Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire de Biologie Médicale [Saint-Mandé, France], Hôpital d'Instruction des Armées Bégin, Académie de Médecine Militaire Française [Ecole du Val-de-Grâce, Paris], Ecole du Val-de-Grâce [Paris, France], Department of Population, Family and Reproductive Health [Baltimore, MD, USA], Johns Hopkins Bloomberg School of Public Health [Baltimore], Johns Hopkins University (JHU)-Johns Hopkins University (JHU), This work was supported by the following French institutions / agencies: 'Agence Nationale de recherche sur le Sida et les hépatites virales' (ANRS), 'Institut national pour la prevention et l'éducation pour la santé' (INPES), 'Caisse nationale militaire de seÂcurite sociale' (CNMSS)., Dupuis, Christine, and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)
- Subjects
Male ,European People ,Physiology ,lcsh:Medicine ,Social Sciences ,Pathology and Laboratory Medicine ,urologic and male genital diseases ,Chlamydia Infection ,Cultural Anthropology ,Governments ,0302 clinical medicine ,5. Gender equality ,Public health surveillance ,Sociology ,Risk Factors ,Reproductive Physiology ,Copulation ,Prevalence ,Medicine and Health Sciences ,Ethnicities ,Public Health Surveillance ,030212 general & internal medicine ,French People ,Young adult ,Chlamydia ,lcsh:Science ,Depression (differential diagnoses) ,Reproductive health ,education.field_of_study ,Multidisciplinary ,virus diseases ,Middle Aged ,female genital diseases and pregnancy complications ,3. Good health ,Bacterial Pathogens ,Religion ,Military personnel ,Military Personnel ,Infectious Diseases ,Chlamydia Trachomatis ,Medical Microbiology ,Female ,France ,Sexual Health ,Pathogens ,0305 other medical science ,Research Article ,Adult ,medicine.medical_specialty ,Sexual Behavior ,Political Science ,Population ,Sexually Transmitted Diseases ,Microbiology ,03 medical and health sciences ,Young Adult ,medicine ,Humans ,education ,Microbial Pathogens ,030505 public health ,Bacteria ,business.industry ,Public health ,lcsh:R ,Organisms ,Biology and Life Sciences ,[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie ,Anthropology ,People and Places ,Sexual orientation ,lcsh:Q ,Population Groupings ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,Self Report ,business ,Armed Forces ,Demography - Abstract
Introduction Sexually Transmitted Infections (STIs) have always represented a public health concern in the military, yet most studies rely on self-reports among non-random samples of military populations. In addition, most of the studies exploring STI rates among the military focus on US service members. This paper assesses the prevalence and correlates of STIs in the French military using biomarkers and compares self-reported versus diagnosed STIs. Methods Data are drawn from the COSEMIL study, a national sexual health survey conducted in the French military in 2014 and 2015. A random sample of 784 men and 141 women aged 18–57 years completed a self-administered questionnaire and provided biological samples for STI testing. We used logistic regression modeling to identify the correlates of STI diagnosis and self-reports. Results The prevalence of diagnosed STIs was 4.7% [3.8–5.9], mostly due to Chlamydia trachomatis. This rate was four times higher than the 12 months self-reported rate of 1.1% [0.6–2.3]. Reported STI rates were similar among men and women (1.1% versus 1.8%), but diagnosed STI rates were twice as high among females versus males (10.4% versus 4.1%, p = 0.007). There were significant differences in the determinants of reported versus diagnosed STIs. In particular, age and sexual orientation were associated with reported STIs, but not with diagnosed STIs. Conversely, STI counseling and depression were associated with STI diagnosis but not with STI reports. Conclusion This study underlines the need to use biomarkers in population-based surveys, given the differential and substantial underreporting of STIs. Results also highlight the need for programmatic adaptation to address gender inequalities in STI rates, by developing women’s health services in the French military. Addressing such needs not only benefits women but could also serve as a strategy to reduce overall STI rates as most military women have military partners, increasing the risk of internal transmission.
- Published
- 2018
- Full Text
- View/download PDF
43. Clinical Signs and Blood Test Results Among Humans Infected With Zoonotic Simian Foamy Virus: A Case-Control Study
- Author
-
Edouard Betsem, Antoine Gessain, Olivier Hermine, Chanceline Bilounga Ndongo, Thomas Montange, Florence Buseyne, Richard Njouom, Epidémiologie et Physiopathologie des Virus Oncogènes (EPVO (UMR_3569 / U-Pasteur_3)), Institut Pasteur [Paris]-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS), University of Yaoundé [Cameroun], Centre Pasteur du Cameroun, Réseau International des Instituts Pasteur (RIIP), Ministère de la Santé Publique [Cameroun], Laboratory of molecular mechanisms of hematologic disorders and therapeutic implications (ERL 8254 - Equipe Inserm U1163), Imagine - Institut des maladies génétiques (IMAGINE - U1163), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire d'Excellence : Biogenèse et pathologies du globule rouge (Labex Gr-Ex), Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), This work was supported by the Institut Pasteur, the Programme Transversal de Recherche, Institut Pasteur (PTR 437), and the Agence Nationale de la Recherche (grant ANR-10-LABX-62-IBEID and REEMFOAMY project ANR-15-CE-15-0008-01)., We thank the study participants, the Institut de Recherche pour le Développement, for their support for the field work, the staff of the Centre Pasteur du Cameroun, Dr Bernard Metogo (Centre des Urgences de Yaoundé), Dr Irène Onana Metogo (Hôpital Jamot de Yaoundé), Agnès Durand (Laboratoire de Biologie Médicale Volontaires-Cerballiance), and A. Fontanet, for statistical analysis., ANR-10-LABX-0062,IBEID,Integrative Biology of Emerging Infectious Diseases(2010), ANR-15-CE15-0008,REEMFOAMY,L'infection humaine par les virus foamy simiens zoonotiques : rôle des facteurs virologiques et immunologiques dans la restrcition de l'emergence virale(2015), Buseyne, Florence, Integrative Biology of Emerging Infectious Diseases - - IBEID2010 - ANR-10-LABX-0062 - LABX - VALID, L'infection humaine par les virus foamy simiens zoonotiques : rôle des facteurs virologiques et immunologiques dans la restrcition de l'emergence virale - - REEMFOAMY2015 - ANR-15-CE15-0008 - AAPG2015 - VALID, Institut Pasteur [Paris] (IP)-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS), and Ministère de la Santé Publique [Yaoundé, Cameroun]
- Subjects
0301 basic medicine ,Male ,Physiology ,Simian foamy virus ,MESH: Simian foamy virus ,MESH: Basophils ,chemistry.chemical_compound ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,Immunology and Allergy ,MESH: Animals ,Cameroon ,[SDV.MP.VIR] Life Sciences [q-bio]/Microbiology and Parasitology/Virology ,[SDV.MHEP.ME] Life Sciences [q-bio]/Human health and pathology/Emerging diseases ,MESH: Aged ,[SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases ,Retrovirus ,MESH: Middle Aged ,biology ,medicine.diagnostic_test ,MESH: Blood Chemical Analysis ,Middle Aged ,MESH: Case-Control Studies ,3. Good health ,Basophils ,Infectious Diseases ,[SDV.IMM.IA]Life Sciences [q-bio]/Immunology/Adaptive immunology ,MESH: Young Adult ,[SDV.IMM.IA] Life Sciences [q-bio]/Immunology/Adaptive immunology ,MESH: Retroviridae Infections ,[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology ,[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,Adult ,Anemia ,030106 microbiology ,Physical examination ,03 medical and health sciences ,Young Adult ,[SDV.MHEP.PED] Life Sciences [q-bio]/Human health and pathology/Pediatrics ,Lactate dehydrogenase ,medicine ,Blood test ,Animals ,Humans ,Aged ,Creatinine ,[SDV.MHEP.PED]Life Sciences [q-bio]/Human health and pathology/Pediatrics ,MESH: Humans ,business.industry ,Case-control study ,Cardiorespiratory fitness ,MESH: Adult ,zoonosis ,hemoglobin ,MESH: Cameroon ,medicine.disease ,biology.organism_classification ,MESH: Male ,030104 developmental biology ,chemistry ,Case-Control Studies ,business ,Blood Chemical Analysis ,simian foamy virus ,Retroviridae Infections - Abstract
International audience; Background. A spillover of simian foamy virus (SFV) to humans, following bites from infected nonhuman primates (NHPs), is ongoing in exposed populations. These retroviruses establish persistent infections of unknown physiological consequences to the human host. Methods. We performed a case-control study to compare 24 Cameroonian hunters infected with gorilla SFV and 24 controls matched for age and ethnicity. A complete physical examination and blood test were performed for all participants. Logistic regression and Wilcoxon signed rank tests were used to compare cases and controls. Results. The cases had significantly lower levels of hemoglobin than the controls (median, 12.7 vs 14.4 g/dL; P = .01). Basophil levels were also significantly lower in cases than controls, with no differences for other leukocyte subsets. Cases had significantly higher urea, creatinine, protein, creatinine phosphokinase, and lactate dehydrogenase levels and lower bilirubin levels than controls. Cases and controls had similar frequencies of general, cutaneous, gastrointestinal, neurological, and cardiorespiratory signs. Conclusions. The first case-control study of apparently healthy SFV-infected Cameroonian hunters showed the presence of hematological abnormalities. A thorough clinical and laboratory workup is now needed to establish the medical relevance of these observations because more than half of cases had mild or moderate anemia. Clinical Trials Registration. NCT03225794.
- Published
- 2018
- Full Text
- View/download PDF
44. CDA as a predictive marker for life-threatening toxicities in patients with AML treated with cytarabine
- Author
-
Raphaelle Fanciullino, Laure Farnault, Joseph Ciccolini, L'Houcine Ouafik, Bruno Lacarelle, Yael Berda-Haddad, Vadim Ivanov, Régis Costello, Mélanie Donnette, Geoffroy Venton, Diane-Charlotte Imbs, Catherine Roche, Simulation & Modelling : Adaptive Response for Therapeutics in Cancer (SMARTc unit), Centre de Recherches en Oncologie biologique et Oncopharmacologie (CRO2), Aix Marseille Université (AMU)- Hôpital de la Timone [CHU - APHM] (TIMONE)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Aix Marseille Université (AMU)- Hôpital de la Timone [CHU - APHM] (TIMONE)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d’hématologie et de thérapie cellulaire, Hôpital de la Conception [CHU - APHM] (LA CONCEPTION), Laboratoire de Biologie médicale, AP-HM, Assistance Publique - Hôpitaux de Marseille (APHM), Aix Marseille Université (AMU)- Hôpital de la Timone [CHU - APHM] (TIMONE)-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire de Transfert d'Oncologie Biologique [Hôpital Nord - APHM], Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital Nord [CHU - APHM], SMARTc, and Hôpital Nord [CHU - APHM]-Assistance Publique - Hôpitaux de Marseille (APHM)-Aix Marseille Université (AMU)
- Subjects
Adult ,Male ,0301 basic medicine ,Antimetabolites, Antineoplastic ,medicine.medical_specialty ,medicine.medical_treatment ,Down-Regulation ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Gastroenterology ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Predictive Value of Tests ,Cytidine Deaminase ,Internal medicine ,medicine ,Humans ,Young adult ,Genotyping ,Aged ,Aged, 80 and over ,Chemotherapy ,Predictive marker ,business.industry ,Cytarabine ,Myeloid leukemia ,Hematology ,Cytidine deaminase ,Middle Aged ,3. Good health ,Leukemia, Myeloid, Acute ,030104 developmental biology ,030220 oncology & carcinogenesis ,Predictive value of tests ,Female ,Erratum ,business ,Biomarkers ,medicine.drug - Abstract
Cytarabine (Ara-C) is the backbone of acute myeloid leukemia (AML) chemotherapy. Little is known about possible risk factors predictive for the frequent (ie, up to 16%) life-threatening or lethal toxicities caused by Ara-C. Ara-C is detoxified in the liver by a single enzyme, cytidine deaminase (CDA), coded by a gene known to be highly polymorphic. In this proof-of-concept study, we particularly investigated the role of the CDA poor metabolizer (PM) phenotype in Ara-C toxicities. CDA phenotyping (measurement of CDA residual activity in serum) and genotyping (search for the CDA*2 allelic variant) were performed in 58 adult patients with AML treated with the standard 7+3 (Ara-C + anthracyclines) protocol. Statistically significantly lower CDA activity was observed in patients experiencing severe/lethal toxicities as compared with patients who did not (1.5 ± 0.7 U/mg vs 3.95 ± 3.1 U/mg; Student t test P < .001). Subsequent receiver operating characteristic analysis identified a threshold in CDA activity (ie, 2 U/mg) associated with PM syndrome and increased risk of developing severe toxicities. Five percent of patients experienced lethal toxicities, all displaying CDA PM status (1.3 ± 0.5 U/mg). In terms of efficacy, a trend toward higher response rates and longer progression-free survival and overall survival were observed in patients with low CDA activity. Taken together, the results of this study strongly suggest that CDA is a predictive marker of life-threatening toxicities in patients with AML receiving induction therapy with standard Ara-C.
- Published
- 2018
- Full Text
- View/download PDF
45. HLA-DRB3/4/5 mismatches are associated with increased risk of acute GVHD in 10/10 matched unrelated donor hematopoietic cell transplantation
- Author
-
Virginie Moalic, A. Parissiadis, Mauricette Michallet, Matthieu Filloux, Florent Delbos, Marie-Thérèse Rubio, Edouard Forcade, Patrice Chevallier, A. Dormoy, Xavier Lafarge, Virginie Renac, Anne Cesbron, Béatrice Pédron, Christophe Picard, Pascale Loiseau, Abdelali Boudifa, Kahina Amokrane, Federico Garnier, F Quainon, Dominique Masson, Peter van Endert, Françoise Hau, M Fort, Raphaël Porcher, Ibrahim Yakoub-Agha, Valérie Dubois, Isabelle Jollet, Julie Bonneau, Etienne Daguindau, Natacha Maillard, Gérard Socié, Anne Kennel, Jacques-Olivier Bay, Anne Devys, Erwann Quelvennec, Régis Peffault de Latour, Stéphanie Ducreux, Myriam Labalette, Claude-Eric Bulabois, Muriel De Matteis, Etablissement français du sang - Auvergne-Rhône-Alpes (EFS), Hôpital Saint-Louis, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Service de neurophysiologie clinique (CHRU Lille), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Laboratoire d'Immunologie (EA 2686), Université de Lille, Droit et Santé, Service d'hématologie [Hôpital Edouard Herriot - HCL], Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Service d'Hématologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Composantes innées de la réponse immunitaire et différenciation (CIRID), Université Bordeaux Segalen - Bordeaux 2-Centre National de la Recherche Scientifique (CNRS), Département de cancérologie et d'hématologie, CHU Grenoble-Hôpital Michallon, Service d'hématologie, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Etablissement français du sang [Angers], Laboratoire de Génétique Moléculaire et d'Histocompatibilité [Brest], Hôpital Morvan [Brest]-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Etablissement français du sang - Normandie (EFS), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Anthropologie bio-culturelle, Droit, Ethique et Santé (ADES), Aix Marseille Université (AMU)-EFS ALPES MEDITERRANEE-Centre National de la Recherche Scientifique (CNRS), Diabète de Type 1 : mécanismes et traitements immunologiques, Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire d'histocompatibilité et d'immunogénétique [Angers], Université d'Angers (UA), Développement du Systeme Immunitaire, Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Contrôle de la Réponse Immune B et des Lymphoproliférations (CRIBL), Université de Limoges (UNILIM)-Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST FR CNRS 3503)-Centre National de la Recherche Scientifique (CNRS), AP-HP Hôpital universitaire Robert-Debré [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Laboratoire de Biologie Médicale [Rennes], Etablissement français du sang [Rennes] (EFS Bretagne), Etablissement Français du Sang - Grand Est (EFS - alsace strasbourg), CHU Toulouse [Toulouse], Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté]), Centre hospitalier universitaire de Poitiers (CHU Poitiers), Etablissement français du sang [Poitiers] (EFS), Centre hospitalier universitaire de Nantes (CHU Nantes), Etablissement Français du Sang [Nantes], CHU Clermont-Ferrand, Etablissement français du sang [Clermont-Ferrand] (EFS), Agence de la biomédecine [Saint-Denis la Plaine], Hopital Saint-Louis [AP-HP] (AP-HP), Immunogénétique humaine, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Département d'épidémiologie, biostatistique et recherche clinique, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Institut Universitaire d'Hématologie (IUH), Université Paris Diderot - Paris 7 (UPD7), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Etablissement français du sang [Bourgogne-Franche-Comté] (EFS BFC), Université Paris Diderot - Paris 7 (UPD7)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon)-Hôpital Jean Minjoz, CHU Pitié-Salpêtrière [APHP], Centre National de la Recherche Scientifique (CNRS)-Université de Limoges (UNILIM)-Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST FR CNRS 3503), Etablissement français du sang [Bourgogne-France-Comté] (EFS [Bourgogne-France-Comté]), CHU Saint Louis [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris]
- Subjects
Oncology ,medicine.medical_specialty ,Hematopoietic cell ,business.industry ,[SDV]Life Sciences [q-bio] ,Hazard ratio ,Hematology ,Disease ,Matched Unrelated Donor ,3. Good health ,Transplantation ,03 medical and health sciences ,0302 clinical medicine ,Increased risk ,Unrelated Donor ,030220 oncology & carcinogenesis ,Internal medicine ,medicine ,business ,030215 immunology ,HLA-DRB3 - Abstract
International audience; Matching for HLA‐A, ‐B, ‐C, and ‐DRB1 loci (8/8 match) is currently the gold standard for unrelated donor hematopoietic cell transplantation (HCT). In Europe, patients are also matched at the HLA‐DQB1 loci (10/10 match). However, there is increasing evidence that matching at HLA‐DRB3/4/5 loci may help to lower transplant‐related morbidity and mortality. We therefore investigated the impact of HLA‐DRB3/4/5 mismatches on outcomes in 1975 patients who received a first 10/10 matched unrelated donor (MUD) HCT in France from 2000 to 2012 for a hematological malignancy. High‐resolution typing was performed at HLA‐A, ‐B, ‐C, ‐DRB1, ‐DQB1, ‐DPB1, and ‐DRB3/4/5 loci for all donor/recipient pairs. Compared with DRB3/4/5‐matched pairs, patients who received a MUD HCT from a DRB3/4/5 mismatched donor had a significantly increased risk of grade II‐IV acute graft‐versus‐host disease (aGVHD) (Adjusted Hazard Ratio (HR) 1.43 (1.07 to 1.90)) associated with lower graft‐versus‐host disease‐free and relapse‐free survival (GRFS) (Adjusted HR 1.20 (1.02 to 1.42)). Conversely, we observed no differences in terms of chronic GVHD, nonrelapse mortality, relapse and overall survival. However, we believe that patients stand to benefit from DRB3/4/5 loci being considered for unrelated donor selection to improve GRFS and then quality of life after unrelated HCT.
- Published
- 2018
- Full Text
- View/download PDF
46. Detection of numerous HIV-1/MO recombinants in France
- Author
-
Elyanne Gault, Fabienne De Oliveira, Véronique Lemée, Jean-Christophe Plantier, Véronique Schneider, Alice Moisan, Thomas Mourez, Marie-Laure Chaix, Marc Wirden, Laurence Bocket, Jean-Dominique Poveda, Magali Bouvier-Alias, Charlotte Pronier, Pierre Cappy, Elodie Alessandri-Gradt, Odile Morvan, Groupe de Recherche sur l'Adaptation Microbienne (GRAM 2.0), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Université de Caen Normandie (UNICAEN), Normandie Université (NU), Laboratoire de virologie [Rouen], Hôpital Charles Nicolle [Rouen]-CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Département de microbiologie : Bactério, Virologie, Parasito, Hygiène, Service de virologie [Rennes], Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-CHU Pontchaillou [Rennes], Laboratoire de virologie [CHU Lille], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Laboratoire de Virologie CHU Henri Mondor, Service de microbiologie [Saint-Louis], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de Microbiologie et Hygiène [AP-HP Hôpital Ambroise-Paré], Hôpital Ambroise Paré [AP-HP], Laboratoire de Biologie Médicale CH Saint Brieuc, Laboratoire CERBA, Laboratoire CERBA [Saint Ouen l'Aumône], Service de virologie [Hôpital Tenon], CHU Tenon [APHP], Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Normandie Université (NU)-Normandie Université (NU)-Département de microbiologie : Bactério, Virologie, Parasito, Hygiène-Hôpital Charles Nicolle [Rouen]-CHU Rouen, Laboratoire de Virologie [Rennes] = Virology [Rennes], CHU Pontchaillou [Rennes], Service de Virologie [Lille], Hôpital Henri Mondor, Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre hospitalier Saint-Brieuc, CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université de Caen Normandie (UNICAEN), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), and AP-HP Hôpital Ambroise-Paré [Boulogne-Billancourt]
- Subjects
Adult ,Male ,0301 basic medicine ,Serotype ,Genotyping Techniques ,Sequence analysis ,030106 microbiology ,Immunology ,Human immunodeficiency virus (HIV) ,HIV Infections ,medicine.disease_cause ,law.invention ,Serology ,Evolution, Molecular ,03 medical and health sciences ,law ,Genetic variation ,medicine ,Humans ,Immunology and Allergy ,Serotyping ,ComputingMilieux_MISCELLANEOUS ,Recombination, Genetic ,business.industry ,Genetic Variation ,Sequence Analysis, DNA ,Middle Aged ,Viral Load ,Virology ,3. Good health ,Genetic divergence ,030104 developmental biology ,Infectious Diseases ,[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology ,HIV-1 ,Recombinant DNA ,Female ,France ,business ,Viral load - Abstract
BACKGROUND The broad genetic divergence of HIV-1/O relative to HIV-1/M has important implications for diagnosis, monitoring and treatment. Despite this divergence, some HIV-1/M+O dual infections and HIV-1/MO recombinant forms have been reported, mostly in Cameroon, where both groups are prevalent. Here, we describe the characteristics of such infections detected in France in 10 new patients, and discuss their implications for biological and clinical practice, owing to the presence of group O species. METHODS The French National Reference Centre for HIV received samples within the framework of mandatory notification of HIV infections, and for expert analysis. A strategy combining serotyping, viral quantification, group-specific molecular amplification and whole-genome sequencing was used for strain characterization and complementary investigations. RESULTS We identified one patient with M+O infection, three patients with M+O infection associated with an MO recombinant, and six patients with only an MO recombinant. These atypical infections were detected upon strain characterization (n = 4) or because of anomalies during patient monitoring (n = 6). We identified eight new URF_MO, all but one originating from Cameroon. Interestingly, two distinct recombinant strains were found in two unrelated patients, representing possible precursors of a CRF_MO. CONCLUSION Our work highlights the fact that the continuous evolution of HIV can hinder diagnosis and complicate clinical practice. We stress that unexpected results during diagnosis or monitoring necessitate further serological and molecular exploration, these atypical infections influence biological and therapeutic management and necessitate appropriate tools, and specific surveillance is necessary, especially as the frequency of such infections may be underestimated.
- Published
- 2018
- Full Text
- View/download PDF
47. A prospective matched study on symptomatic dengue in pregnancy
- Author
-
Jean-Pierre Duvernois, Sibille Everhard, Célia Basurko, Hélène Hilderal, Gabriel Carles, Marion Restrepo, Larissa Valmy, Rachida Boukhari, Séverine Matheus, Anne Favre, Mathieu Nacher, Véronique Lambert, Centre d'investigation clinique Antilles-Guyane (CIC - Antilles Guyane), Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pointe-à-Pitre/Abymes [Guadeloupe] -CHU de la Martinique [Fort de France]-Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française], Centre National de Référence pour les Arbovirus - Laboratoire de Virologie [Cayenne, Guyane française] (CNR - laboratoire associé), Institut Pasteur de la Guyane, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP), Réseau International des Instituts Pasteur (RIIP), Centre Hospitalier de l'Ouest Guyanais, Laboratoire de Biologie Médicale, Centre Hospitalier de l'Ouest Guyanais Franck Joly (Saint-Laurent-du-Maroni), Service de gynécologie et d’obstétrique [Kourou, Guyane française] (Croix Rouge Française), Centre médico-chirurgical de Kourou [Guyane française], Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française], Laboratoire de Mathématiques Informatique et Applications (LAMIA), Université des Antilles (UA), and Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU de la Martinique [Fort de France]-CHU Pointe-à-Pitre/Abymes [Guadeloupe] -Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française]
- Subjects
0301 basic medicine ,Viral Diseases ,Physiology ,Maternal Health ,lcsh:Medicine ,Blood Pressure ,Dengue virus ,medicine.disease_cause ,Pathology and Laboratory Medicine ,Vascular Medicine ,Dengue fever ,Dengue Fever ,Cohort Studies ,Dengue ,Labor and Delivery ,0302 clinical medicine ,Pregnancy ,Risk Factors ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,Medicine and Health Sciences ,Birth Weight ,030212 general & internal medicine ,Prospective Studies ,Pregnancy Complications, Infectious ,Prospective cohort study ,lcsh:Science ,[SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases ,Multidisciplinary ,Obstetrics ,Obstetrics and Gynecology ,3. Good health ,French Guiana ,Infectious Diseases ,Physiological Parameters ,Hypertension ,Female ,Cohort study ,Research Article ,Neglected Tropical Diseases ,Adult ,medicine.medical_specialty ,030106 microbiology ,Hemorrhage ,[SDV.MHEP.GEO]Life Sciences [q-bio]/Human health and pathology/Gynecology and obstetrics ,Preterm Birth ,03 medical and health sciences ,Young Adult ,Signs and Symptoms ,Diagnostic Medicine ,Hypertensive Disorders in Pregnancy ,medicine ,Humans ,Seroconversion ,business.industry ,Cesarean Section ,lcsh:R ,Body Weight ,Infant, Newborn ,Infant ,Biology and Life Sciences ,Dengue Virus ,Infant, Low Birth Weight ,medicine.disease ,Tropical Diseases ,Preeclampsia ,Infectious Disease Transmission, Vertical ,Pregnancy Complications ,Relative risk ,Birth ,Small for gestational age ,Women's Health ,lcsh:Q ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,business - Abstract
International audience; Dengue fever is an increasing problem worldwide, but consequences during pregnancy remain unclear. Much of the available literature suffers from methodological biases that compromise the validity of clinical recommendations. We conducted a matched cohort study during an epidemic in French Guiana to compare events and pregnancy outcomes between two paired groups of pregnant women: women having presented with symptomatic dengue during pregnancy (n = 73) and women having had neither fever nor dengue during pregnancy (n = 219). Women in each arm were matched by place of follow up, gestation weeks at inclusion, and place of residence. Dengue infection was considered to be confirmed if viral RNA, N S1 antigen, the seroconversion of IgM antibodies or the presence of IgM was detected in collected samples. According to the 2009 WHO classification, 27% of the women with symptomatic dengue had at least one clinical or biological warning sign. These complications occurred after the 28th week of gestation in 55% of cases. The medical history, socioeconomic status and demographic characteristics were included in multivariate analysis. Exposure to dengue during pregnancy was not significantly associated with pre-maturity, small for gestational age infants, hypertension or emergency caesarian section. Maternal dengue with warning signs was a risk factor for peripartum hemorrhage with adjusted relative risk = 8.6(95% CI = 1.2-62). There was a near significant association between dengue and in utero death (p = 0.09). This prospective comparative study underlined the importance of taking into account potential confounders between exposure to den-gue and the occurrence of obstetrical events. It also confirms the need for increased vigilance for pregnant women with dengue, particularly for women who present with severe dengue. PLOS ONE | https://doi.org/10.1371/journal.pone.
- Published
- 2018
- Full Text
- View/download PDF
48. Quantification of HPV16 E6/E7 mRNA Spliced Isoforms Viral Load as a Novel Diagnostic Tool for Improving Cervical Cancer Screening
- Author
-
Céline Loubatier, Philippe Halfon, Valérie Giordanengo, Anne Plauzolles, Xavier Carcopino, Sébastien Vitale, Guillaume Penaranda, Hacène Khiri, Claire Camus, Institut méditerranéen de biodiversité et d'écologie marine et continentale (IMBE), Centre National de la Recherche Scientifique (CNRS)-Institut de recherche pour le développement [IRD] : UMR237-Aix Marseille Université (AMU)-Avignon Université (AU), Service de Gynécologie-Obstétrique, CHU Marseille, Hôpital Nord, AP-HM, 13015 Marseille, France., CHU Marseille, Microbes évolution phylogénie et infections (MEPHI), Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU), Avignon Université (AU)-Aix Marseille Université (AMU)-Institut de recherche pour le développement [IRD] : UMR237-Centre National de la Recherche Scientifique (CNRS), ALPHABIO - Laboratoire de biologie médicale, Bases, Corpus, Langage (UMR 7320 - UCA / CNRS) (BCL), Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA), and Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS)
- Subjects
0301 basic medicine ,Gene isoform ,high risk human papillomaviruses (HPVs) infection ,cervical cancer ,lcsh:Medicine ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Cervical intraepithelial neoplasia ,Article ,03 medical and health sciences ,0302 clinical medicine ,medicine ,Pap test ,Cervical cancer ,Messenger RNA ,medicine.diagnostic_test ,business.industry ,lcsh:R ,qRT-PCR ,General Medicine ,medicine.disease ,Molecular biology ,3. Good health ,Reverse transcription polymerase chain reaction ,030104 developmental biology ,Real-time polymerase chain reaction ,030220 oncology & carcinogenesis ,grade 2 or higher cervical intraepithelial neoplasia ,HPV16 E6/E7 mRNA viral loads ,business ,Viral load ,diagnostic tool - Abstract
High-risk human papillomaviruses (HPVs) have been identified as the main contributors to cervical cancer. Despite various diagnostic tools available, including the predominant Papanicolaou test (Pap test), technical limitations affect the efficiency of cervical cancer screening. The aim of this study was to evaluate the diagnostic performance of spliced HPV16 E6/E7 mRNA viral loads (VL) for grade 2 or higher cervical intraepithelial neoplasia diagnosis. A new dedicated (quantitative reverse transcription polymerase chain reaction) qRT-PCR assay was developed, allowing selective quantification of several HPV16 E6/E7 mRNA: Full length (FL) with or without all or selected spliced forms (total E6/E7 mRNA corresponding to SP + E6^E7 mRNA (T), + spliced E6/E7 mRNA containing intact E7 ORF (SP), and E6/E7 mRNA containing disrupted E6 and E7 ORFs calculated by the following subtraction T-SP (E6^E7)). Twenty HPV16 DNA and mRNA positive uterine cervical smears representative of all cytological and histological stages of severity were tested. We have shown that all E6/E7 mRNA isoforms expression levels were significantly increased in high grade cervical lesions. Statistical analysis demonstrated that the SP-E6/E7 VL assay exhibited: (i) The best diagnostic performance for identification of both cervical intraepithelial neoplasia (CIN)2+ (90% (56&ndash, 100) sensitivity and specificity) and CIN3+ (100% (72&ndash, 100) sensitivity and 79% (49&ndash, 95) specificity) lesions, (ii) a greater sensitivity compared to the Pap test for CIN2+ lesions detection (80% (44&ndash, 97)), (iii) a predictive value of the histological grade of cervical lesions in 67% of atypical squamous cells of unknown significance (ASC-US) and 100% of low-grade (LSIL) patients. Overall, these results highlight the value of SP-E6/E7 mRNA VL as an innovative tool for improving cervical cancer screening.
- Published
- 2018
- Full Text
- View/download PDF
49. SURVEILLANCE DES INFECTIONS HUMAINES PAR HANTAVIRUS EN FRANCE MÉTROPOLITAINE, 2012-2016
- Author
-
Reynes, Jean-Marc, Carli, Damien, Renaudin, Béatrice, Fizet, Alexandra, Bour, Jean-Baptiste, Brodard, Véronique, Cart-Tanneur, Emmanuelle, Dewilde, Annie, Hamri, Mohamed, Fleury, Hervé, Hecquet, Denise, Jeulin, Hélène, Lechat, Sylvie, Lemarquand-Bardini, Maud, Lepiller, Quentin, Poveda, Jean-Dominique, Raulin, Olivia, Twizeyimana, Eterne, Cauteren, Van, Velay, Aurélie, Septfons, Alexandra, Baize, Sylvain, Biologie des Infections Virales Émergentes - Biology of Emerging Viral Infections (UBIVE), Centre International de Recherche en Infectiologie - UMR (CIRI), Institut National de la Santé et de la Recherche Médicale (INSERM)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut Pasteur [Paris], Centre National de Référence des Hantavirus - Biologie des Infections Virales Emergentes (CNR-UBIVE), Institut Pasteur [Paris], Laboratoire de sérologie-virologie (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Laboratoire de Virologie Médicale et Moléculaire - EA 4684 (CardioVir), Université de Reims Champagne-Ardenne (URCA)-Centre Hospitalier Universitaire de Reims (CHU Reims)-SFR CAP Santé (Champagne-Ardenne Picardie Santé), Université de Reims Champagne-Ardenne (URCA)-Université de Picardie Jules Verne (UPJV)-Université de Reims Champagne-Ardenne (URCA)-Université de Picardie Jules Verne (UPJV), Eurofins Biomnis, Centre Hospitalier Universitaire de Lille (CHU de Lille), Centre Hospitalier de Laon (CH Laon), Hôpital Pellegrin, CHU de Bordeaux, CHU Amiens-Picardie, Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Centre Hospitalier de Charleville-Mezières, Centre Hospitalier Louis Pasteur [Dole], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Laboratoire CERBA [Saint Ouen l'Aumône], Laboratoire de Biologie Clinique [CHI Compiègne-Noyon], Centre Hospitalier Intercommunal Compiègne-Noyon (CHI Compiègne-Noyon), Laboratoire de Biologie Médicale [CH de Saint-Quentin], Centre hospitalier de Saint-Quentin, Santé publique France - French National Public Health Agency [Saint-Maurice, France], Laboratoire de Virologie [Hôpitaux universitaires de Strasbourg], Les Hôpitaux Universitaires de Strasbourg (HUS), Le CNR des Hantavirus reçoit un support financier de Santé publique France., Centre International de Recherche en Infectiologie (CIRI), École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut Pasteur [Paris] (IP), Institut Pasteur [Paris] (IP), Université de Reims Champagne-Ardenne (URCA)-Université de Reims Champagne-Ardenne (URCA), Reynes, Jean-Marc, École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), and Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut Pasteur [Paris] (IP)
- Subjects
Surveillance ,[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,France ,Hantavirus - Abstract
Surveillance of human hantavirus infection has been carried out for about 30 years in mainland France. From 2012-2016, a network of 15 clinical laboratories, the National Reference Center (NRC) for Hantavirus and the French Public Health Agency (Santé publique France) were involved in the surveillance. Data were obtainedfrom the analysis of the information sheet records of the hantavirus cases diagnosed by the laboratory network and confirmed by the NRC.The global situation was similar as the ones observed in the previous periods: an average of about one hundred cases, mostly hospitalized, was reported annually (incidence of 0.15 case per 100,000 inhabitants) with high annual variations. Active people were more concerned (median age 40 years), and were mostly males (75% of the cases). Cases were detected all year round with peaks of detection at the end of spring and at fall. Most of the cases were due to Puumala virus, but interestingly Seoul and Tula viruses were also detected, underlying other high-risk behavior. The geographic distribution of the cases in the North-Eastern quarter of France had a limited peripheral extension. However, this incidence and this geographic distribution are probably under-estimated because of the use of too specific serological diagnostic tests, and the low request of laboratory tests outside the hantavirus endemic area or for outpatients., Les infections par les hantavirus chez l'homme font l'objet d'une surveillance en France, en particulier en métropole, depuis une trentaine d'années. Cette surveillance associait sur la période 2012-2016 un réseau d'une quinzaine de laboratoires de biologie médicale, le Centre national de référence (CNR) des Hantavirus et Santé publique France. Les données de surveillance ont été obtenues par l'analyse des fiches de renseignements accompagnant les échantillons des cas diagnostiqués par les laboratoires du réseau et confirmés par le CNR. La situation observée était proche de celles rapportées pour les périodes précédentes : une centaine de cas, la plupart hospitalisés, était dénombrée en moyenne annuellement (incidence de 0,15 cas pour 100 000 habitants) avec de fortes variations annuelles. La population active était toujours la plus touchée (médiane d'âge de 40 ans) et les hommes étaient les plus concernés (75% des cas). Les cas étaient détectés toute l'année, avec des pics de détection à la fin du printemps ou à l'automne. La majorité des cas étaient dus au virus Puumala, mais le fait marquant sur la période était la détection de cas d'infection par les virus Seoul et Tula et la nature des expositions à ces virus. La distribution géographique des cas, concentrée sur le quart nord-est de la France, a connu une extension très limitée dans sa périphérie. Cependant, cette incidence et cette distribution géographique pourraient être sous-estimées du fait de l'utilisation de tests de diagnostic sérologique trop spécifiques et de la faible demande de diagnostic pour des patients non hospitalisés ou en dehors de la zone d'endémie connue.
- Published
- 2017
50. Fever in hospitalized HIV-infected patients in Western French Guiana: first think histoplasmosis
- Author
-
Vincent Vantilcke, Antoine Adenis, Anne Jolivet, Rachida Boukhari, Cyrille Vautrin, Caroline Misslin, Mathieu Nacher, ADENIS, ANTOINE, Service de Médecine, Centre Hospitalier de l'Ouest Guyanais Franck Joly (Saint-Laurent-du-Maroni), Laboratoire de Biologie Médicale, Centre d'investigation clinique Antilles-Guyane (CIC - Antilles Guyane), Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU de la Martinique [Fort de France]-CHU Pointe-à-Pitre/Abymes [Guadeloupe] -Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française], Centre d'Investigation Clinique Antilles-Guyane (CIC - Antilles Guyane), and Université des Antilles et de la Guyane (UAG)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pointe-à-Pitre/Abymes [Guadeloupe] -CHU de Fort de France-Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française]
- Subjects
Male ,Pediatrics ,Opportunistic infection ,HIV Infections ,Prevalence ,Hiv infected patients ,Pharmacology (medical) ,Histoplasmosis ,Coinfection ,Middle Aged ,French Guiana ,Hospitalization ,Infectious Diseases ,Female ,Itraconazole ,medicine.drug ,Adult ,medicine.medical_specialty ,Adolescent ,Fever ,Histoplasma ,Dermatology ,Immunocompromised Host ,Young Adult ,Age Distribution ,Acquired immunodeficiency syndrome (AIDS) ,Disseminated histoplasmosis ,primary prophylaxis ,Amphotericin B ,Weight Loss ,parasitic diseases ,medicine ,Humans ,Medical ward ,Sex Distribution ,Intensive care medicine ,Aged ,Retrospective Studies ,AIDS-Related Opportunistic Infections ,business.industry ,Public Health, Environmental and Occupational Health ,HIV ,medicine.disease ,CD4 Lymphocyte Count ,[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie ,Hiv patients ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,business - Abstract
Summary In Western French Guiana, there was a dramatic increase in HIV prevalence between 1990 and 2000. The present study describes the causes of fever among HIV patients hospitalized in the medical ward of the only hospital in the western part of French Guiana. A retrospective descriptive study was conducted between 1 January 2008 and 30 June 2010 in the department of medicine of Saint Laurent du Maroni Hospital. The main characteristics of 67 patients having presented with fever in the first 48 hours of hospitalization were described. Among patients with CD4 3 the main febrile opportunistic infection was disseminated histoplasmosis (41.1%). Among patients with CD4 counts 3 and fever without focal points 85.7% had disseminated histoplasmosis. Three patients died and all had disseminated histoplasmosis. Disseminated histoplasmosis is the most common febrile opportunistic infection in western French Guiana. Primary prophylaxis with itraconazole among immunocompromised patients seems warranted.
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.